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GENERAL INTRODUCTION 
The total body clearance is the kinetic parameter characterizing the 
elimination of drug from the body. Especially for lipophilic drugs' the 
liver plays an important role in the elimination so that for many drugs 
the total body clearance equals the metabolic clearance. 
The metabolic clearance depends on the kinetics of the metabolic 
enzymes in the liver. This implies that there must be a relationship 
between the parameters governing enzymatic conversion of drugs in the 
liver and the metabolic clearance or total body clearance. 
The object of this study is to explore the relationship between 
total body clearance in vivo and enzymatic processes in vitro. For this 
purpose the kinetics of series of barbiturates were studied in the intact 
rat and preparations of rat liver. The in vitro methods range from studies 
on the intact perfused rat liver via isolated liver cells (hepatocytes) 
to liver microsomes and the enzyme cytochrome Ρ 450. See figure. 
These studies allow us to gain information on the relevance of blood 
flow through the liver, the rate of penetration of drugs within the liver 
cells, access to the microsomes and finally binding to and biotransforma­
tion by the liver enzymes with respect to the rate of metabolic degrada­
tion. 
The barbiturates were chosen because the compounds are strongly re­
lated but nevertheless they show diverse pharmacological properties. The 
discovery of the hypnotic properties of 5,5-diethyl barbituric acid 
(barbital) by Fischer and Von Mehring in 1903 led to the synthesis of 
numerous barbituric acid derivatives. Numerous barbiturates and barbitu­
rate combinations have been introduced into practice as hypnotics, seda­
tives and anaesthetics (Bobranski, 1972). The consumption of barbiturates 
amounts still to enormous proportions so that many cases of barbiturate 
poisoning and fatalities have been reported. 
In early studies with rats and mice it has been found that the 
"hypnotic effect", often expressed as minimum anaesthetic dose (M.A.D.), 
could be changed markedly by varying the substituents. See review by 
Doran (1959), which covers the period before 1956. The hypnotic activity 
in rats is different from the hypnotic potency in man. It is, however, 
11 
Survey of the metabolia systems studied in this thesis. Liver, hepato-
ayte and sahematia representation of the microsomes 
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not a simple parameter but the result of complex processes, as the rela­
tionship between blood concentration and sensitivity condition, which 
vary with species (Stolman, 1960) and sex (Stevenson, 1974) and drug 
properties such as intrinsic activity, distribution through the body and 
especially the rate of elimination. Recent work, therefore, has been 
directed to biotransformation of barbiturates (Mayпегt, 1954; Tsukamoto, 
1958). The relationship between pharmacological effect, kinetic behaviour 
and drug metabolism has, however, not yet been studied. 
The barbiturates are eliminated mainly by metabolic conversion and 
the rate of elimination varies tremendously among the individual com­
pounds. In addition homologous series are available or within our syn­
thetic reach, so that also the relationship between chemical structure 
and rate of elimination could be studied. 
New methods in blood sampling in rats, preparation of hepatocytes 
and sensitive analytical techniques have been developed to ensure the 
analysis of blood concentration curves in individual rats and the study 
on a pool of isolated liver cells. As a result the relationship between 
pharmacological effect and the blood concentration profile could be 
studied and the relationship mentioned could be investigated. Such ex­
periments cannot be done with the common techniques of using pooled data 
from groups 'of rats. 
Finally, the relevance for drug treatment in humans has been dis­
cussed, especially the extrapolation of results in rats to humans. 
13 

SECTION I 
PHARMACOKINETICS 
CHAPTER 1 
KINETICS OF DRUG DISTRIBUTION AND ELIMINATION 
INTRODUCTION 
Drugs introduced into the body of man or animals by enteral or parente-
ral routes are distributed over the entire body and reach their target 
tissues by means of the blood circulation. The drug should reach a suf-
ficiently high concentration at its site of action to cause a pharmaco-
logical response. The interaction of drug molecules with the receptors 
is probably a fast process (Ariens, 1964). This implies that equilibrium 
is reached at the receptors although the concentration of drug in the 
environment of the receptors may change because of absorption and elimi-
nation processes going on. 
The time course of the concentration of drug near the receptors and 
hence the profile of the drug concentration curve in the blood governs 
the intensity of the pharmacological response as a function of time. In 
the intact animal or in man the situation may be more complex since dif-
ferent types of receptors may be activated by the same drug and the 
various effects may mutually influence each other. 
The blood concentration profile depends on the kinetic process, ab-
sorption, distribution and elimination, which occur simultaneously. The 
blood concentration curve can be characterized by a number of kinetic 
parameters if an appropriate model of the body is used. The body may be 
considered to exist of a number of compartments while there is exchange 
of drug between the blood and these compartments and elimination from the 
blood to the environment. Certain compartments show similar properties so 
that they may be grouped together. A two compartment model in general 
provides a good description of blood concentration curve. See Fig. 1.1a. 
Sometimes a single compartment suffices and this is also what one expects 
for a suspension of hepatocytes. See Fig. 1.1b. The volumes of the com-
partments and the clearance constants governing drug transport are the 
important parameters. Following oral administration the drug is deposited 
in the gastro-intestinal tract, which is a compartment outside the body. 
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See Fig. 1.1c. The elementary equations for these three cases will briefly 
be described. Extensive information on this subject, can be found in the 
literature (Dost, 1968; Van Rossum, 1971; Riggs, 1963). 
Kl2 
LkCel jkOri 
k d 
he* 
Fig. 1.1 Block echemes of reapeotively the open bùo-oompartment model, 
the one-aompartment model and oral administration (see text). 
Elimination is aseimed to take place from the central compart-
ment. 
TEE OPEN TWO-COMPARTMENT MODEL 
Pharmacokinetic studies have shown that the elimination of many drugs, 
following intravenous administration, is not a simple exponential process. 
A graph of the logarithm of the drug concentration against the time often 
shows at first a steep decline, followed by a less rapid linear phase. It 
has been found that the two-compartment model is sufficient to describe 
such a curve. 
In the open two-compartment model it is assumed that there is a 
central compartment which represents the fluids and tissues which are 
17 
b l o o d cone, ( m g / l . l o g s c a l e ) 
6 0 -
A i 
( —) hexobarbital (15mg) χ—χ 
hydroxy-metabolite ·—>· 
keto - metabol i te Δ—& 
20 4 0 6 0 8 0 100 120 140 
time ( mm) 
1.2 Blood coneentratian-time ourve following intravenous admini­
stration in a rat. The dotted line (0-—o)3 which represents 
the first term of the two-term exponential equation, can be 
obtained by subtracting the blood concentration values of the 
extrapolated elimination phase from the corresponding values 
on the solid line. Αη and A2 represent the zero-time intercepts 
of respectively the distribution and the elimination components 
of equation 1. The zero-time intercept of the biphasic curve is 
the sum of A* and Л .^ It had to be noticed that metabolites 
appear already after 1 min, so during the distribution simul­
taneously metabolism occurs. 
vascularized so that they instantaneously have the same concentration of 
drug as the blood and a second, or peripheral, compartment which repre­
sents the fluids or tissues which are filled up at a slower rate. Elimi­
nation is assumed to take place from the central compartment because the 
liver and the kidney are highly vascularized. Drug transport is governed 
by the following differential equations: 
dC 
Vl ΊΓ ' - (kCel + kC.2> C| + kC2l C2 (1> 
dC dQ 
V2 ¿Γ - - kC21 C2 + kC12 Cl ^ r = - k C e l C l ( 2) 
Here are V and V. the volume of the compartments, k
r
 _, к , and k_ . 
clearance constants and С and C, the concentration of drug in the cen­
tral and peripheral compartment. These equations lead to the following 
bi-exponential equation for the concentration in the blood: 
-t/τ -t/τ 
C t - A 1 e + Р^ e (3) 
where С is the blood concentration in the central compartment at any 
time (t) after the administration, τ and τ are time constants and A 
and A. the zero-time intercepts of the two components of the bi-exponen­
tial curve (Fig. 1.2). The time constants are complex parameters which 
include all the clearance constants and volumes given in Fig. 1.1a. It 
is common practice to relate the biological half-life to the largest of 
the two time constants (tj = 0.69 τ»). From the four experimental para­
meters the most important pharmacokinetic parameters for a drug in the 
body may be calculated, using the following equation (Van Rossum, 1971): 
kCel * 0 / ( Α Γ ι + г* (4) 
D (τ A + τ A ) 
V f = (x¡A|+T2A2) V . - D / U ^ V (5) 
where D is the dose and V is the apparent volume of distribution, that 
is the volume that would occur if under steady conditions in V_ the same 
19 
concentration would exist as in V . 
In our experiments with intact rats bi-exponential curves were en­
countered which have been analysed according to the two-compartment model. 
THE OPEN ONE-COMPABTMENT MODEL 
When the rate of distribution largely exceeds the rate of elimination, 
there is instantaneously mixing of the drug over the entire body. In this 
case a single compartment suffices to describe the drug profile curve. 
The differential equations reduce according to the model of Fig. 1.1b. 
d Cl d qel 
Vl ΊΓ m - kCel Cl T T * kCel Cl <6> 
The blood levels decrease according to mono-exponential equation 
-t/T
e l 
C t - A e
 e i
 (7) 
where A is the blood concentration at zero-time and τ . the elimination 
el 
time constant. Now V - V . The pharmacokinetic parameters, the elimina­
tion, clearance and the volume of distribution are: 
kCel * D / A Tel V * D / A ( 8 ) 
In our experiments with the isolated perfused liver, the hepatocytes 
and microsomes the concentration curves decrease in a mono-exponential 
fashion and have been analysed according to the one-compartment system. 
ORAL ADMINISTRATION 
In contrast with intravenous administration drugs administered orally 
will not reach the general circulation immediately, but first undergo 
several processes such as transport to the absorption site and the actual 
absorption. Consequently drug concentration in the blood will be initial­
ly equal to zero and increase to a maximum level as a result of drug ab-
20 
blood cone. (mg/I; log scale) 
t '/г «I 270 mio 
30mg butobarbital po 
14days later: 
20mg butobarbital po χ—χ 
•τ 1 1 1 1 1 1 1 1 1 1 1 1 Γ 
4 0 8 0 120 160 200 240 280 
time (mm ) 
Fig. 1.3 Blood aonaentration-tim curvee of butobarbital after oral ad­
ministration of respectively 30 covi 20 mg. The dotted line 
Co o) represents the absorption phase and is obtained by 
subtraction of the blood concentration data during the absorp~ 
tien phase from the corresponding values on the extrapolated 
elimination phase. Note that in these tuo experiments both the 
absorption and the elimination time constant have the same 
value, indicating the reproducibility of experiment in the same 
animal. 
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sorption. The overall rate at which the drug reaches the general circula­
tion (absorption rate) may be determined by measuring blood levels at 
frequent intervals after the drug administration (Fig. 1.3). The time 
course of the blood concentration can be described by a three-term ex­
ponential equation. In many cases absorption is much slower than the dis­
tribution over the body so that the distribution phase is overshadowed 
and the body may be considered as a single compartment. The differential 
equations according to Fig. 1.1c are: 
dC 
V
o ΪΓ
 m
 -
 kCa Co <9> 
d Cl d Qel 
1 dt Ca o Cel 1 dt Cel 1 
Here V is the volume of the zero-compartment and k« the absorption 
clearance. The solution is a bi-exponential equation: 
-t/T -t/τ 
C t - A (e
 e i
 - e
 a ) (11) 
A priori one has no notion whether the entire dose is absorbed. The value 
of A depends on the amount that is absorbed, the apparent volume of dis­
tribution and the time constants τ . and τ . In formula: 
el a 
. F.D Tel ,..,, A =
 v^v
 (,2) 
where F is the bioavailability or the fraction of the dose that is ab­
sorbed. In case of oral studies the clearance and the volume of distribu­
tion are overestimated if F < 1. 
Our experiments following oral administration are analysed according 
to the model of Fig. 1.1c, unless a distribution phase is apparent in the 
curves. 
FLOW-LIMITED ELIMINATION OF DRUGS 
Generally the liver is responsible for the metabolic clearance of drugs. 
Therefore, it is evident that metabolic clearance will be limited by the 
hepatic blood flow. On the other hand the metabolic clearance, however, 
is also determined by the capacity of the enzymes and the affinity of the 
drugs for them. The relationship between this real metabolic clearance 
(k ) and the liver blood flow (kf), resulting in an apparent metabolic 
clearance (k- ), can be given by the following equation: 
-
k
rn/kf 
к
Г т я п п
 = к. (1 - e C m f) (13) 
Lm app r 
When к is large in comparison with the liver blood flow, the apparent 
metabolic clearance approaches the liver blood flow. If the liver blood 
flow is large in comparison with the real metabolic clearance, the ex­
ponential term in eq. 13 is small, so that this term may be developed in 
a series of terms according to a McLaurin series (Nagashima, 1968), re­
sulting in the following equation: 
k„ = k„ (1 - k„ /2k,) (14) 
Cm app Cm Cm f 
When k f » k- the apparent metabolic clearance approaches the real meta­
bolic clearance. 
CAPACITY-LIMITED ELIMINATION 
As mentioned previously the metabolic clearance is also determined by the 
capacity of the liver enzymes. Enzymatic conversion may be described by 
the following equation: 
k, k 3 
E + S ^ I ES — E + Products (15) 
k2 
where E, ES and S are respectively: the enzyme, the enzyme-substrate 
complex and the substrate. Furthermore, per definition: 
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к + к к 
\~-LT¡1 e d K s - k 7 (16) 
where К is the Michaelis-Menten constant. Assuming that the substrate 
m 
concentration in the clearance tissue equals the blood concentration, 
the relationship between the metabolic clearance and the metabolic en­
zymes may be given by: 
- - ^ (17) Cm К + С 
m 
where k_ , 0 and К are respectively: the metabolic clearance, the meta­
bolic capacity of the enzymes and the Michaelis-Menten constant. 
The metabolic clearance, therefore, is not a constant but is essentially 
dependent on the concentration. However, for low drug concentrations 
(C « К ) the metabolic clearance is a constant: 
m 
kCm - V K m <18> 
For most drugs the clearance is a constant in the therapeutic dosage 
range but it is evident that the clearance essentially will become dose-
-dependent at higher doses. This may be encountered in case of intoxica­
tions or suicide attempts with barbiturates. 
PHARMACOKINETIC ANALYSIS 
Pharmacokinetic analysis of the barbiturate blood and perfusate levels 
was accomplished by fitting the experimental data to equation 3 or 7 with 
the aid of Farmfit, a non-linear regression computer program. From the 
fitted A and τ values the pharmacokinetic constants were calculated 
(detailed information on this program is given by Breimer, 1974). 
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CHAPTER 2 
ENZYME KINETICS ON HEPATOCYTES AND MICROSOMES 
The enzyme parameters V and К (or К ) can be calculated from experi-
m m s 
meats in which the rate of formation of a metabolite or eventually the 
rate of decrease of substrate is measured by using various substrate 
concentrations and a constant amount of enzyme. By a double-reciprocal 
plot denoted on the Lineweaver-Burke plot the maximum rate V and the 
r
 m 
Michaelis-Menten constant К can be found from the intercept with the 
m 
ordinate and the abcis respectively. In formula: 
1- J- + !" . I (19) 
ν ν ν · s K J 
m m 
This equation is only valid in the steady state. So it is essential that 
the rate is linear with the time and the activity proportional to the 
enzyme concentration. However, the conditions in such microsomal suspen­
sion may differ considerably from the in vivo situation or in the hepato-
cytes suspension because in both these cases transport processes from 
blood to the endoplasmatic reticulum may have a large influence. Despite 
these uncertainties, it is possible to calculate the enzyme parameters 
in vivo, provided that the drug concentration is high enough (C > Κ , 
see chapter 1). In a microsomal suspension the cellular integrity is lost. 
It is, therefore, of advantage to calculate enzyme constants in intact 
cells or in isolated intact organs. 
The decline in the drug concentration as function of time is given 
by the following equation, which holds also true for drug concentration 
in the order of magnitude of К (Van Ginneken, 1974): 
m 
In С = In A + Ц ^ - — (20) 
m el 
where С and A are respectively: the concentration at any time (t) and the 
initial concentration extrapolated to zero-time. When the drug concentra­
tion drops to such levels that С < К by metabolic conversion the equa-
m 
tion reduces to the well-known linear equation. This implies that from 
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the straight part of the curve at low concentration τ can be calcu­
lated and from the non-linear part also К . 
m 
It is now possible to correlate the К values calculated from en-
m 
zyme experiments as well as from liver microsomes, hepatocytes and intact 
liver preparations. Deviations may be due to transport barriers which may 
be different for the different barbiturates. A further correlation is 
possible with the binding (K ) to cytochrome Ρ 450, the enzyme ultimately 
responsible for enzymatic conversion. 
It has been shown that drugs reacting with cytochrome Ρ 450 cause a 
characteristic spectral change of the enzyme (Remmer, 1966), while these 
spectral changes are due to binding to the enzyme (Schenkman, 1967). From 
a plot of the spectral difference against the concentration of drug it is 
possible to calculate К . r
 s 
The relationship between k_ . or τ , and К (or К ) dictates that r
 Cel el m s' 
the smaller К , the smaller τ . It is then possible to gain rapidly in­
formation from in vitro experiments whether difficulties might be ex­
pected in vivo. 
Since we have included in our study homologous series of barbiturates 
it is also possible to study the influence of gradual changes in the mole­
cule on the enzyme constants and elimination rate constants as well as on 
their mutual connection. 
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SECTION II 
MATERIALS AND METHODS 
CHAPTER 3 
SYNTHESIS OF BARBITURATES 
Barbiturates not conmercially available were synthesized by condenzing 
the appropriate ethyl-alkyl diethyl malonates with urea (Fischer, 190A). 
The malonates were prepared from diethyl malonate (Fluka A.G., Switzer­
land) and the alkyl bromides according to the method of Shonle (1930). 
Their boiling points are listed in Table 3.1. 
TABLE 3.1 
Boiling points of some alkyl substituted 
diethyl malonates, used for the synthesis 
of 5-ethyl-5-alkyl substituted barbiturates 
R 
Pentyl 
Hexyl 
Heptyl 
Octyl 
Nonyl 
C 2 H 5 4 
< 
mol.wt. 
202 
216 
230 
244 
258 
^СООСз н 5 
4COOC2 H 5 
B.P. 
92- 94OC/0.5 mm 
114-116oC/1.0 mm 
130-131OC/1.0 mm 
110-112oC/0.4 mm 
162-1640C/1.5 mn 
N-metylated barbiturates were prepared by methylation with dimethyl-
sulphate (B.D.H. Chemicals Ltd., England) according to the method of 
Martin (1966). Both the mono-methyl and the dimethyl derivatives were 
obtained, which can be separated easily. All barbiturates were crystal­
lized from ethanol/water (for melting points see Table 10.2). The methyl 
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derivatives of the 5-ethyl-5-alkyl series separated from the recrystal-
lization solvent as an oil. 
The barbiturates were checked on purity by G.C. and G.C. combined 
mass spectrometry (L.K.B. 9000). The purity was more than 99%. All other 
reagents were of analytical grade. All barbiturates were applied as their 
sodium salts by dissolving the free acid in 1 m-NAOH and adjusting to pH 
9.0 with 1 nr-HCl, except the dimethyl derivatives, which were suspended 
in perfusate solution (see chapter 5). 
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CHAPTER 4 
INTACT ANIMAL EXPERIMENTS 
ANIMALS 
Male Wistar rats, weighing 200-300 g, were used. The animals were kept 
on a standard laboratory diet and fasted overnight before the experi-
ment, but had free access to water. 
ADMINISTRATION 
Intravenous administration was performed by injecting the barbiturates 
into the dorsal penis vein. Applied in this way the drug reaches the 
general circulation rapidly (Nightingale, 1971). A wrongly applied in-
jection is easily discovered by the swelling of the penis, whereas in 
the more conmonly used tail injection control is more difficult. The 
mean injection time was approximately 10 sec. Oral administration was 
carried out with a stomach tube. 
SAMPLING 
At regular intervals blood samples of 0.3-0.4 ml were taken by orbita 
punction, using Hawksley heparinized micro-haematocrit centrifuge tubes 
(Cat.no. A 803). The blood was collected in tubes containing one drop 
of héparine. This method of sampling is very suitable for obtaining 
small blood samples rapidly, which is important in following the fast 
distribution of a drug after intravenous administration. Detailed in-
formation on this sampling method can be found in the literature (Hal-
pern, 1951). 
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SLEEPING AND LATENTION TIMES 
Sleeping times were determined by measuring the time between the loss 
and the regain of the righting reflex. Latention time was considered as 
the time between the injection and the loss of the righting reflex. 
EVALUATION OF THE METHOD 
Pilot experiments in which the time course was followed for a long 
period (3-4 times the apparent half-life) showed that the terminal 
phase was logarithmic linear. Therefore, the number of samples during 
this period can be restricted. It is sufficient to take 3-4 samples 
during the first 10 min and 5-6 during the disposition phase to charac-
terize the blood concentration-time curve. 
Since there were considerable variations in metabolic activity between 
the animals, series of barbiturate homologues were studied in the same 
animal. The barbiturates were administered to the same animal in random 
order with interims of two weeks. Moreover, in each series of experi-
ment a reference compound was included (see chapter 5). 
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CHAPTER 5 
THE ISOLATED PERFUSED RAT LIVER 
PERFUSION APPARATUS 
The perfusions were mainly performed according to the method of Miller 
et al. (1951). In Figure 5.1 a schematic drawing is shown of the recir­
culating perfusion system used. The essential operating principles are 
as follows: the perfusion medium is brought to the top of the oxygenator 
by means of a roller рипф. A filter, obtained from a disposable blood 
transfusion set, prevents clots of blood from entering the circulation. 
The perfusate flows down as a film along the walls of the oxygenator and 
is collected at the bottom. From the bottom of the oxygenator the per­
fusate is supplied to the liver, while the excess of medium runs through 
the bypass to the reservoir. The oxygenator was adjusted to give a hydro­
static pressure of 20 cm H.O. Thus a constant liver blood flow of about 
10-15 ml/min.g liver was maintained. The perfusate leaving the liver by 
the vena cava reaches the reservoir passing a calibrated tube and is 
again sucked into the pump. The perfusate is oxygenated with a counter 
current stream of a moistened mixture of 95% 0» and 5% CO., which enters 
the reservoir, then reaches the oxygenator via the bypass and leaves the 
oxygenator at the top. The whole system is placed in a thermostatically 
controlled cabinet (temperature 39 C). 
Samples of about 0.7 ml were drawn with a 1 ml disposable syringe 
from the connection tube between the reservoir and the pump. The liver 
blood flow was determined by measuring the time needed to fill the cali­
brated cuvet below the liver, which was placed on a perforated sheet in 
the organ chamber. At regular times the pH; pO. and pCO. before and after 
the passage through the liver were measured. 
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Fig. 5.1 Schematic dmuing of the apparatus used for the isolated per-
fused rat liver 
33 
OFEBATIVE TECHNIQUE 
The liver donor rats were anaesthesized with ether, the abdomen was 
opened via a mid-line incision. After cutting the oesophagus between 
ligatures, the bile duct was located and cannulated with a polyethylene 
tube (Portex Ltd., England). The animal was then heparinized by inject-
ing 1 ml héparine (1000 i.u.) into the spleen. Three loose ligatures 
were passed around the portal vein, which was then cannulated with a 
Braunula (G 16, B. Braun Melsungen A.G., West Germany, size 2 R) and 
the ligatures were tied, securing the cannula in place. Following these 
procedures the thorax was opened, the vena cava cut and the liver hang-
ing on the diaphragm was transferred to the organ chamber. Care was 
taken to avoid admission of air into the cannula when connecting it with 
the system. About 2-4 min elapsed between the cannulation of the portal 
vein and the start of the perfusion. Extensive reports on liver perfusion 
and operation techniques have been published in the literature (Scholz, 
1968). 
PERFUSION MEDIUM 
The volume of the perfusate was 200 ml and consisted of 80 ml freshly 
washed dog erythrocytes, 60 ml Hank's Eagle solution (Hanks Bss Dried, 
Code 5071) and 60 ml Ringer solution to which was added 6 g albumine 
(Sigma, no. A-4503), 400 mg glucose and 15 drops of terгашуcine. 
PERFORMANCE AND PHYSIOLOGICAL CONTROL OF THE PERFUSION 
A skilful cannulation of the liver and connection with the apparatus 
should result in a uniform red-brown colour of the liver surface. Bile 
production should start immediately. Since the medium contains phenol 
red, this compound will be excreted in the bile giving it a red colour. 
The pO. before and after the liver was about 250 and 40 mm Hg res­
pectively, the p0_ deficit being constant for nearly 6 hours. Livers 
which showed a low p0_ deficit after equilibration for half an hour were 
34 
discarded. The bile flow was ranging from 1.5-2.0 ml in 4 hours, which 
is in agreement with the values found by Ostahever (1960). 
EVALUATION OF THE METHOD 
A possible disappearance of barbiturates from the perfusate due to meta-
bolism by the perfusate or adsorption to the tubes or walls of the system 
was checked. Perfusions without liver showed that these processes did not 
take place. Two examples with lipophilic barbiturates are shown in Figure 
5.2. 
perfusate cone (mg/ l , log scale) 
100 
e o J (10 mg) 
60-
Fig. 5.2 Control perfusion without liver of S-ethyl-5-oatyl barbituric 
acid (6)°- and ReoticbnR (12)a 
a. mean half-lives (min) with liver in -parentheses (see chapters 
11 and 12) 
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In contrast with the reports of Klaassen (1971) on biliary excre-
tion of barbiturates, in our perfusion studies the amount of barbiturate 
excreted unchanged in the bile was always less than 0.5% of the dose ad-
ministered (Fig. 5.4). Therefore, the disappearance of barbiturate from 
the perfusate can be attributed to metabolism by the liver. 
The routine criteria for the performance of the liver as bile pro-
duction, liver blood flow and oxygen consumption proved to be unsuitable 
to quantify the metabolic activity of the liver. The metabolic conver-
sion of a reference compound was used as a sort of internal standard for 
each perfusion. Heptabarbital (5-ethyl-5-cycloheptenyl barbituric acid) 
was chosen as the reference compound for the following reasons: 
1. Heptabarbital is eliminated mainly by metabolic conversion; no un-
changed barbiturate could be detected in the urine, following admini-
stration in rats (Bernard, 1957). 
2. Neither heptabarbital nor its metabolites interfere in G.C. analysis 
with most of the barbiturates studied. 
3. It is metabolized rapidly, so there is enough time left to study an-
other barbiturate. 
With respect to the last point, it was important to investigate 
whether heptabarbital is eliminated flow-dependent. It was found that 
with flow rates higher than 15 ml/min, which is also the rate in intact 
rats (Liehr, 1972), heptabarbital elimination is flow-independent (Figure 
5.3). In order to avoid flow-dependent elimination of the fast metaboliz-
ed barbiturates, rather high flow rates were used. Comparison with per-
fusions at lower flow rate? showed that these high flow rates did not 
damage the liver. 
The perfusions were carried out according to the following standard 
scheme: 
1. Equilibration for half an hour, during which time the physiological 
condition of the liver was checked. 
2. In the following hour heptabarbital was introduced into the perfusate 
and 8 samples at intervals of 4 min were taken to estimate the hepta-
barbital clearance. Usually no more heptabarbital could be detected 
after 40 min. 
3. After 60 min the barbiturate in study was introduced into the perfu-
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sion fluid. At the introduction of each barbiturate the bile collect­
ing vessel was replaced by another. 
liver blood flow (ml/mm) 
MO-i 
5 0 
2 0 
10 
-o-o-o-o-o-o 
perfusate concentiMion (m$/l ) 
бОт 
CO 4 0 6 0 0 0 100 ICO WO 160 
hme ( m m ) 
Fig. 5.3 Influenae of the liver blood flow on heptabarbital alearanoe. 
Lowering the flow to 7 ml/min affects the oleavanae. An de­
crease, however, from 32 to 15 ml/min has no effect on the 
clearance. 
An example of the usefulness of the standardization is given in 
Figure 5.4. Administration of heptabarbital and the barbiturate in study 
according to a cross over design did not change the heptabarbital half-
-life and clearance ratio. 
A drawback of the method is that a possible interference with meta­
bolites of a previously administered barbiturate cannot be excluded. 
However, barbiturates have been reported to be converted in hydroxy- and 
keto-metabolites, which are much less lipophilic than their parent com­
pounds (Bush, 1973) and will have, therefore, a lower affinity to the 
37 
perfusate cone ( m g / l . log scale ) 
time (min) 
Fig. 5.4 Сотграгівоп of the time courses of heptabarbital and Talbutal 
(5-allyl-5-(l-methyl propyl) barbituria acid) in two different 
perfusions „ 
• fteptabarbital (8 mg) A Talbutal perfusion 
10-9-74 
О heptabarbital (8 mg) Δ Talbutal perfusion 
12-9-74 
vertical bars: cumulative biliary excretion of Talbutal" (vg) 
metabolic enzymes. Figure 5.5 shows that a high dose of hydroxy-hexobar-
bital only slightly affects the time course of the parent compound. 
In our studies, determination of clearance values have been per­
formed using whole blood (perfusate) concentrations. The clearance of a 
drug by the liver cannot exceed the liver blood flow. Using plasma 
clearances, one has to reckon with a possible difference with the whole 
blood (perfusate) clearance, due to differences in binding to erythro­
cytes or plasma (perfusate) protéines. Such differences in clearance 
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perfusate cone (mg/l;log scale) 
6 0 
4 0 
2 0 
10-
sì ^J—^ . J 
20 40 60 Θ0 
time ( mm) 
Fig. 5.5 Influenae of S-hydnOxy-hexobarbitat on clearanoe of hexobarbi-
tal by the -isolated perfused rat liver 
• 12 mg hexobarbital (control) 
© 12 mg hexobarbital at time 30 min 
20 mg hydroxy-metabolite at time 25 min 
have been reported for nortriptyline and desmethylimipramine (Rowland, 
1972). Barbiturate binding to albumine (Goldbaum, 1954) and to erythro­
cytes (Brodie, 1953) seems to increase with higher lipophilicity. Pos­
sibly, the binding and debinding of barbiturates to these blood components 
is a rate limiting step in the metabolism of barbiturates. Differences in 
the rate of metabolism have been reported for hexobarbital enantiomers, 
whereas the proteine binding showed no significant differences (Breimer, 
1974). It seems, therefore, unlikely that binding of barbiturates to 
blood components is a rate limiting factor in barbiturate metabolism. 
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CHAPTER 6 
9000 G LIVER SUPERNATANT 
In this study, liver homogenates represent the most simplified enzyme 
system with metabolizing activity. In preliminary studies on hydroxyla-
tion of barbiturates, no difference could be found between the 9000 g 
rat liver supernatant and the microsomal fraction, so that for con­
venience the first enzyme preparation has been chosen. 
PREPARATION OF THE LIVER SUPERNATANT 
Livers of male Wistar rats were excised immediately after decapitation 
and washed with ice-cold Tris buffer pH 7.4 (0.05 M) containing KCl 
(0.15 M). The livers were weighed, pooled and then homogenized with 4 
R 
parts (w/v) of buffer in a Potter-Elvehjem homogenizer with a Teflon 
pestle. Then the homogenate was centrifugad for 20 min in a refrigated 
centrifuge (MSE, high speed 18) at 9000 g. 
INCUBATION CONDITIONS 
The incubation volume was 30 cc and consisted of 5 ml barbiturate solu­
tion (10 mg/lOO ml Trie pH 7.4), 5 ml liver supernatant, 5 ml of a NADPH-
-regenerating system and 15 ml Tris pH 7.4. 
The NADPH-regenerating system contained per 100 ml: 650 mg isocitric acid 
(Sigma, no. 1-1252), 200 mg NADP (Boehringer, Mannheim), 5 ml 0.1 M MgCl2 
0.5 ml 0.1 M MnCl-, 1 ml isocitric dehydrogenase (Sigma, no. 1-2002, type 
IV; capable of generating 5.5 pmol NADPH/min.mg at 370C) and 93.5 ml 
Tris-HCl buffer pH 7.4. 
The mixture without barbiturate was pre-incubated at 37 С for 15 min 
to ensure reduction of all NADP. The reaction was started by adding the 
barbiturate solution. At various time intervals samples of 1 ml were 
taken and transferred to tubes containing 7 ml ether and internal stan-
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dard. 
EVALUATION OF THE METHOD 
The incubation method adopted from Dewaide (1968) in which aeration was 
performed by shaking, proved to be unsatisfactory for experiments with 
barbiturates. The curves were often non-linear and the rate of disap­
pearance of substrate from the incubation mixture was low (Fig. 6.1, I). 
concentralion (mg/l log scale) 
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4 0 
2 0 -
1 0 -
β -
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Fig. 6.1 Evaluation of the 9000 g rat liver supernatant incubation. 
Rate of disappearance of heptabarbital CO. 13 rnnol), incubated 
under various conditions in a shaking waterbath at 37°C. 
I 0.11 rmol NADP; without carbogen 
II 0.11 rmol NADP; with aarbogen 
III 0.22 rmol NADP; with aarbogen 
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The requirement for molecular oxygen in the cytochrome Ρ 450-tiiediated 
metabolism of drugs is well documentated (McMahon, 1969; Politzer, 1971). 
The addition of substrate to a microsomal suspension, containing a NADPH-
-regenerating system, increases the oxygen consumption (Wolf, 1974). 
Cumming (1970) has shown a relationship between the metabolism of hexo-
barbital and the oxygen tension, which in the perfused liver and in the 
intact rat became rate limiting at oxygen tensions below 45 mm Hg. 
Therefore, we have improved the oxygenation and varied the amount of 
NADP. 
In subsequent experiments it was found that bubbling a mixture of 
0 2 and CO. (95:5) through the incubation medium resulted in a initial 
increase in disappearance rate of heptabarbital, followed by a decrease, 
probably caused by oxidation of NADPH. Doubling the amount of NADP in 
the regenerating system increased the linearity of the curve and lowered 
the half-life (Fig. 6.1). Higher amounts of NADP had no effect on the 
half-life. 
It was found that an adequate oxygenation could be performed by 
stirring the incubation mixture, so that bubbling of gas through the 
medium, often resulting in the formation of foam, could be omitted (Fig. 
6.2). The experiments were carried out in the apparatus shown in Figure 
6.3. As internal control for the activity of the enzyme preparation the 
elimination of heptabarbital was taken (see chapter 5). 
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Fig. 6.2 Evaluation of the 9000 g rat liver supernatant inaubation. 
Rate of disappearance of heptabarbital (0.06 m!fol)3 inoubated 
with 0.22 mMol NADP undsr various eonditicns. 
I aeration by shaking 
II with oarbogen and stirring 
III only stirring 
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Fig. 6.3 Sahematio drawing of the apparatus used for the 9000 g rat 
liver supernatant and the hepatocyte experiments 
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CHAPTER 7 
ISOLATED RAT HEPATOCYTES 
INTRODUCTION 
Metabolic studies with suspensions of isolated rat hepatocytes represent 
a new metabolic model system, in which the intracellular structures re-
main intact. Mechanical separation or treatment of the liver with EDTA 
have already been described (Branster, 1957; Kaltenbach, 1952). These 
methods, however, proved to be ineffective as they produced a poor yield 
of cells which, moreover, often revealed extensive cellular damage 
(Berry, 1962). 
The discovery of enzymatic methods to isolate intact rat paren-
chymal cells successfully (Berry, 1969; Howard, 1968) initiated the 
development of a metabolic tool, which has found an ever increasing 
employment. In this study we have isolated rat liver parenchymal cells 
according to the methods described by Seglen (1973) and Bojar (1975), 
with slight modifications. 
ISOLATION PROCEDURE 
Male Wistar rats weighing 200-300 g were used and fasted overnight 
before the experiment. After heparinizing the animal by injecting 1 ml 
of héparine (5000 i.u.) into the spleen, the liver was first perfused in 
situ through the portal vein for 5 min at a rate of about 50 ml/min, 
with a warm (37 C), 0 saturated, Ca -free buffer (buffer I) in order 
to wash the blood from the liver, while free outflow was obtained by 
cutting the lower vena cava. Cannulation of the portal vein was done 
R 
with a Braunula . While still being perfused, the liver was cut loose 
from the body and placed in an organ chamber as was used for the liver 
perfusions and the perfusion was continued for 10 min. Following this, 
the perfusion was switched over to a warm (37 C), 0« saturated, colla-
genase buffer (buffer II) . After recirculating perfusion for 15 min, 
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the liver was transferred to a Petri dish and gently dispersed in buffer 
III . The suspension was then filtered through nylon mesh of 250 μ pore 
size and the volume adjusted to 75 ml with suspension buffer. The cells 
were shaken for half an hour at 37 С (damaged cells agrégate) and fil-
tered through nylon mesh of 100 μ poor size. Further removal of cell 
debris was accomplished by differentiate centrifuging four times for 5 
min at 300 rpm. Between the centrifugings, the cells were resuspended in 
75 ml of ice-cold buffer IV . The final pellet was resuspended in buffer 
a . 
Ill in the required cell concentration. 
Liver cell concentrations were quantitated by counting aliquots of 
the suspension in a Bürker-TÜrk counting chamber to which 0.6% Trypan 
Blue was added. Cell yields ranged from 300-500 χ 10 intact cells per 
liver, about 10% of which was stained with Trypan Blue. 
EVALUATION OF THE METHOD 
Incubation in glass stoppered tubes in a rotary shaker at 37 С (Notten, 
1975) proved to be unpractical, because of the rapid elimination of the 
barbiturates and the amount of samples to be taken. Therefore, the ex­
periments were carried out in the apparatus described for the 9000 g ex­
periments (Fig. 6.3). After pre-incubation for 15 min, to 25 ml cell 
suspension 5 ml barbiturate solution (10 mg/100 ml buffer III) was added. 
The final cell concentration ranged from 2-3 χ 10 /ml. 
Starting the incubation in this way, it was found that the repro­
ducibility was low and the concentration-time curves often showed a 
deviation from linearity. It was found that again the oxygen supply was 
the critical parameter in these experiments. Bubbling the incubation 
mixture with carbogen, increased the linearity of the curves consider­
ably but often led to formation of foam. At least, the oxygen capacity 
a 
Note: Composition of buffers I-IV, see Seglen (1973). 
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was increased by the addition of freshly washed dog erythrocytes. This 
proved to be quite satisfactory (Fig. 7.1). Control experiments showed 
that in incubations with erythrocytes, but without hepatocytes, there 
was no drug metabolizing activity. 
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Fig. 7.1 Influenae of inoúbatian conditiens on ths elimination of 1-N-
-methylayalobarbital (16.S mg/l) by isolated rat hepatocytes 
A. in presence of carbogen 
Б. in presence of dog erythrocytes 
С only stirring 
• 1-N-methylcyclobarbital 
Δ hydroxy-metabolite 
π keto-metabolite 
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The rate of elimination of the barbiturates from the incubation 
vessels appeared to be proportional to the hepatocyte concentration 
(Fig. 7.2). In order to obtain measurable half-lives, 2-3 χ 10 cells/ml 
was chosen as the final hepatocyte concentration. 
30 Time (mm) 
Fig. 7.2 Influence of cell conoentratian on heptabarbital elimination 
Cell aona.xlO^/ml k-
 7 (ml/min) 
A. 20 A. 0.099 
B. 10 B. 0.041 
С 5 С. 0.021 
D. 2.5 D. 0.013 
Finally, the following incubation composition was chosen: 
5 ml barbiturate solution (10 mg/100 ml buffer III), 10 ml erythrocyte 
Eagle solution (1:1 v/v) and 15 ml hepatocyte suspension. 
With respect to the high affinity of the more lipophilic barbitu­
rates to hepatocytes (see chapter II), non-linear kinetics due to satura­
tion could not be excluded. The concentration of barbiturate in the hepa­
tocytes can be affected considerably by the addition of another binding 
possibility, e.g. albumin to the medium. Therefore, in the case of 
saturation, addition of albumin would result in a decrease of half-life. 
Figure 7.3 shows the influence of increasing albumin concentrations on 
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the half-l i fe of heptabarbital. From these results i t may be concluded 
that the elimination of barbiturate is not dose-dependent under the con­
ditions described. 
2 0 
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Fig. 7.3 Influence of albumin conaentration on elimination of heptabar­
bital (0.067 mMol) by isolated rat hepatocytes 
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CHAPTER 8 
PARTITION COEFFICIENTS 
As already mentioned in chapter 1 the effect of a drug depends on its 
concentration in the biophase and its affinity to the receptor(s). This 
implies that transport processes of a drug to that biophase, which in-
volves passage through hydrophilic and lipophilic barriers, is an im-
portant factor in determining the biological response. The transport to 
and the binding at the active site will depend, among other things, on 
the hydrophobic character of the drug, which can be measured in a parti-
tion system. Octanol/water partition coefficients of a number of barbi-
turates have been reported already in the literature (Hansch, 1967). 
Therefore, we have also used this system for comparison purposes. In 
addition another reference partition system was used, namely isolated 
hepatocytes/water in view of the metabolism of barbiturates, which 
mainly takes place in the liver. 
OCTANOL/WATER PARTITION COEFFICIENTS 
5 ml octanol solution containing 20 mg barbiturate per 100 ml was shaken 
vigorously for half an hour with an equal volume of phosphate buffer 
(Sorensen, 1/15 Mol). Both phases were saturated previously with each 
other. After equilibration and centrifuging the two layers were separated. 
The partition coefficient was calculated from the decrease of concentra-
tion in the octanol layer. Because of the large differences in the parti-
tion of the various barbiturates, the measurements has to be performed at 
different pH's. From these apparent partition coefficients (APC) the true 
partition coefficient (TPC) could be calculated using the following for-
pH-pK. 
mula: TPC - APC (I + 10 ). 
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HEPATOCYTES/WATER PARTITION COEFFICIENTS 
To 2 ml of a cell suspension, containing 4 χ 10 cells, was added 60 pg 
barbiturate. After stirring gently for 10 min, during which equilibration 
was reached, the suspension was centrifuged. Under these conditions no 
metabolism by the hepatocytes took place. From the ratio cells/water the 
AFC at pH 7.4 was calculated. 
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CHAPTER 9 
SPECTRAL DISSOCIATION CONSTANTS (K ) 
s 
К values were determined with the help of difference spectra according 
to the method of Janssen (1972). 
PREPARATION OF MICROSOMES 
Livers of male Wistar rats were excised immediately after decapitation, 
weighed, transferred to 9 vol. ice-cold 0.25 M sucrose and homogenized 
in a Potter-Elvehjem homogenizer. Nuclei and cell debris were sedimen-
tated by centrifuging at 600 g for 5 min; the supernatant was centrifuged 
at 18000 g for 15 min; the microsomal fraction was obtained by centri­
fuging the 18000 g supernatant for 1 h at 105000 g. The microsomal pellet 
was resuspended in 0.15 M KCl and centrifuged at 105000 g for 30 min, to 
remove haemoglobin and finally resuspended in 4 vol. 0.15 M KCl - 0.05 M 
Tris-HCl (pH 7.4) to a concentration of about 1 mg microsomal protein 
per ml. The barbiturates were dissolved in KCl-Tris-HCl buffer to con­
centrations ranging from 0.02-2 mMol. Two cuvettes were filled with 1 ml 
microsomal suspension and 2 ml barbiturate solution was added to the 
suspension, while to the reference cuvet an equal volume of buffer was 
added. With varying substrate concentrations, spectra were recorded from 
500-350 nm on a Carry 118 С double beam spectrophotometer with a scat­
tered transmission accessory. The extent of spectral change was deter­
mined as the difference in absorption at 420 and 390 nm. К values were 
r
 s 
obtained from reciprocal plots with the help of a linear regression com­
puter program. 
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CHAPTER 10 
ANALYSIS 
Barbiturate concentrations were determined by means of gas chromato-
graphy according to Jain (1967). 
EXTRACTION PROCEDURE 
Blood and artificial fluid samples were extracted with 5 ml ether-ace-
tone (1:1 v/v) on a whirlmixer. The extract was evaporated to dryness, 
the residue was redissolved in ethanol and analysed by G.C. Tissue 
samples were first homogenized in acetone, saturated with tartaric acid 
according to a modified method described by Kisser (1968). The acetone 
layer was evaporated to dryness and the residue redissolved in hot water. 
After heating for 15 min in a waterbath at 80 C, the solution was fil-
tered and the filtrate extracted twice with ether. The ether layer was 
evaporated to dryness and the residue dissolved in ethanol. In order to 
correct variations in extraction a known amount of another barbiturate 
was added to the sample and used as internal standard. The concentration 
was calculated with the aid of a factor, derived from linear calibration 
curves. These curves were constructed by adding known amounts of barbi-
turate to blood or tissue and plotting the peak area ratio barbiturate/ 
standard to the concentration ratio barbiturate/standard. An example of 
these calibration curves is shown in Figure 10.1. The recovery was about 
90 per cent, for the fluid samples and somewhat lower, about 75 per cent., 
for the tissue samples. Concentrations down to 100 ng/ml blood and 60 ng/g 
tissue could be determined. 
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peak orea brallobarbital 
peak area heptabarbital 
14-
T I S S U E S RAT B L O O D 
1 0 15 2 0 
cone brollobarbital 
cone heptabarbital 
Fig. 10.1 Calibration graphs for the determination of brallobarbital in 
blood and tissues, using heptabarbital as internal standard 
Blood samples: χ extraction with ether 
• extraction with ether-acetone 
Δ extraction with tartaric acid-acetone 
GAS CHEOMATOGRAPHY 
Gas chromatographic analysis was done on a Hewlett-Packard gas Chroma­
tograph, type 402, equipped with a nitrogen detector. The nitrogen de­
tector is very useful in the analysis of nitrogen containing compounds 
as barbiturates. The use of a nitrogen detector results in an increase 
not only of sensitivity but also of selectivity when compared with the 
normal flame ionization detector, as has been discussed extensively by 
Breimer (1973). The 0V-17 column, which has been used, seperates clearly 
53 
barbiturate metabolites from the parent compounds (Table 10.1). Column 
and oven conditions were: glass column (1.8x3 mm I.D.) packed with 3% 
0V-17 on gas-chrom Q, 60-80 mesh; oven temperature 220-240 C, inlet and 
detector temperature were 260 С and 300 С respectively. Helium was used 
as carrier gas at a flow rate of 25-30 ml/min; hydrogen and oxygen flow 
rates were 30 and 200 ml/min respectively. In Table 10.2 the relative 
retention times are shown of the barbiturates used in this study, to­
gether with their melting points. 
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TABLE 10.1 
Retention time ratio metabolite to parent 
compound of a number of barbiturates 
Compound 
Pentyl 
Hexyl 
Heptyl 
Octyl 
Nonyl 
Dm-Hexyl 
Seco 
Reet 
ш-Bral 
m-Cyclop 
Нехо 
m-Cyclo 
m-Hepta 
m-Rep 
Пш-Сусіо 
m-Нехо 
Metabolite I 
2.91 
2.59 
2.58 
2.56 
2.68 
2.49 
2.22 
0.74 
0.76 
2.43 
2.21 
2.11 
2.26 
2.15 
2.05 
1.78 
Metabolite II 
2.15 
2.66 
2.67 
2.56 
2.71 
2.45 
2.21 
Temp.(0C) 
240 
240 
240 
240 
240 
210 
230 
240 
230 
230 
240 
240 
230 
240 
230 
230 
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TABLE 10.2 
Relative retention times and melting points 
of a number of barbituric acid derivatives 
Drugs Rel. ret. time m.p. 
230° С 250° С 0° С 
Propyl 
Butyl 
Pentyl 
i-Pentyl 
s-Pentyl 
Dm-but 
Hexyl 
Heptyl 
Octyl 
Nonyl 
m-Hexyl 
m-Heptyl 
m-Octyl 
m-Nonyl 
Dm-Hexyl 
Alio 
Арго 
Tal 
Neal 
Seco 
Bral 
m-Bral 
Dm-Bral 
Noct 
Eunarc 
18.9 
22.6 
30.6 
24.2 
29.0 
32.3 
39.5 
51.6 
72.6 
95.2 
28.2 
35.5 
48.4 
64.5 
20.2 
22.6 
21.8 
25.0 
27.4 
33.9 
61.3 
35.5 
24.2 
61.3 
37.1 
21.4 
25.7 
34.3 
27.1 
30.0 
32.9 
42.9 
54.3 
75.7 
97.1 
28.6 
37.1 
48.6 
65.7 
22.9 
24.3 
25.7 
27.1 
30.0 
35.7 
65.7 
38.6 
28.6 
65.7 
42.8 
139-142 
124-126 
130-132 
155-157 
127-129 
151-154 
124-126 
117-119 
114-117 
104-107 
167-170 
140-141 
224-225 
154-155 
94- 96 
164-168 
97- 99 
36- 38 
178-180 
108-110 
1) The retention time of he^tabarbital has been taken as 100 
2) After rearystallization from ethanol/water (see chapter 3) 
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TABLE 10.2 
continued 
Drugs Rel. ret. time p.m. 
230° С 250° С 0° С 
Pern 
m-Pem 
Reet 
Cyclop 
m-Cyclop 
Nor-hexo 
Hexo 
ш-Нехо 
Cyclo 
m-Cyclo 
Dm-Cyclo 
Hep ta 
m-Hepta 
Dm-Hepta 
m-Pheno 
Rep 
m-Re ρ 
Hydroxy-hexo 
Keto-hexo 
80.7 
4 8 . 4 
92.7 
5 4 . 8 
3 6 . 3 
66.9 
4 6 . 8 
35.5 
77 .4 
5 0 . 8 
3 6 . 3 
100.0 
6 8 . 6 
5 3 . 2 
5 7 . 3 
131.7 
85.5 
109.7 
138.7 
8 0 . 0 
5 1 . 1 
9 4 . 3 
5 7 . 1 
4 0 . 0 
6 8 . 6 
5 0 . 0 
37.1 
7 9 . 4 
5 1 . 8 
4 0 . 0 
100.0 
6 8 . 6 
5 3 . 9 
5 8 . 2 
128.6 
8 8 . 6 
102.9 
131.4 
132-133 
7 9 - 83 
163-165 
137-139 
7 9 - 80 
207-109 
145-147 
7 5 - 76 
150-153 
103-105 
6 2 - 64 
175-176 
9 5 - 97 
6 0 - 61 
178-179 
212-215 
164-166 
180-185 
160-162 
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SECTION III 
PHARMACOKINETICS OF BARBITURATES 
CHAPTER 1 1 
5-ETHYL-5-ALKYL SUBSTITUTED BARBITURATES 
IN THE RAT AND IN THE LIVER PERFUSION 
INTRODUCTION 
This group of barbiturates has been derived directly from 5,5-diethyl 
barbituric acid (barbital). The chemical structures of the barbiturates 
are listed in Table 11.1. Butobarbital, qua structure the first deriva­
tive of barbital used in treatment of insomnia, was developed in 1922 
and is widely used as a hypnotic drug with an intermediate duration of 
ρ 
activity (Martindale, 1972) and is marketed under the trade name Soneryl . 
R 
Amobarbital (Amytal ), which was introduced in 1923, has a similar mini­
mum anaesthetic dose (M.A.D.) as butobarbital but with a shorter duration 
of action. The same was found for pentobarbital (Nembutal ) which in 
addition to its use in human sleep therapy is also extensively used as 
veterinary anaesthetic. The hexyl derivative (Ortal ) is the latest deri­
vative of the series, vhich is used in clinical medicine. However, there 
are only a few reports on this barbiturate (Lorhan, 1944). Following 
intravenous administration in dogs (Gruber, 1937), Ortal was reported 
to produce anaesthesia lasting only one third as long as that of amobar­
bital. As far as known, the remaining derivatives of the series have not 
been employed in clinical medicine. 
The major route of elimination of barbiturates is metabolism in the 
liver. In order to investigate the role of the liver in the elimination 
of the drug independent of distribution processes and other routes of 
elimination, the isolated perfused rat liver was selected, which can be 
considered as an in vitro system nearest to the intact animal and forming 
a link with the more simplified systems as liver slices, isolated hepato-
cytes and the 9000 g supernatant of liver homogenates. 
In this chapter an attempt was made to compare the pharmacokinetics 
of this series of barbiturates in the intact rat and in the isolated 
perfused rat liver and to relate the findings to the physico-chemical 
properties of the drugs. 
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TABLE I 1.1 
Chemical structure, apparent (APC at pH 7.4) and true 
(TPC) partition coefficients of a number of barbiturates 
_ _ 
C-C C - N 
С o o 
R' 4C — N' 
II 
0 H 
Compound R pK log TPC log APC log APC 
octanol/water cells/water 
Propyl -C-C-C 7.90 0.87 0.66 -0.13 
7.86 1.70 1.26 0.15 
8.00 2.23 1.78 0.43 
8.03 2.13 1.73 0.38 
7.87 2.11 1.58 0.40 
7.86 2.39 2.02 0.52 
8.00 3.08 2.46 0.80 
Heptyl -C-C-C-C-C-C-C 8.00 3.64 2.91 1.35 
Octyl -C-C-C-C-C-C-C-C 8.00 3.85 3.08 1.97 
Nonyl -C-C-C-C-C-C-C-C-C 8.00 4.13 3.30 2.29 
1) From Doornbos (1969); Krahl (1940) and Sitsen (1973) 
Generic name: a. butobarbitai 
b. pentobarbital 
a. amobarbital 
Butyl3 
Pentyl 
s-Pent 
i-PentC 
Dm-but 
Hexyl 
-c-c-c-c 
-c-c-c-c-c 
-ç-c-c-c 
с 
-C-C-Ç-C 
-C-Ç-Ç-C 
-C-C-C-C-C-C 
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HESULTS 
Intact rat experiments 
Intravenous administration of the barbiturates resulted in biphasic blood 
concentration-time curves, shown in Figure 11.1. The first rapid fall in 
blood concentration lasted 5-10 min and is mainly due to distribution in 
the tissues. After the distribution phase there is a second phase which 
represents overall elimination. In Table 11.2 the half-lives of this 
elimination phase are presented as well as the ratio to heptabarbital 
half-life. Large differences in the half-lives of barbiturates in rats 
are reported in the literature. For the s-pentyl derivative the values 
range from 120 min (Pelkonen, 1973) to about 50 min (Alvarez, 1973; 
Siemens, 1973), while for the i-pentyl derivative values have been de-
termined in the magnitude of 60 min (Pelkonen, 1973) and 150 min (Misra, 
1974). Possibly interstrain differences are responsible for these varia-
tions. The values found by Pelkonen support our findings that the half-
-life of the i-pentyl derivative is shorter than that of the s-pentyl 
homologue. Table 11.2 indicates that the half-lives decrease with in-
creasing chain length. The apparent volumes of distribution of the 
homologous series do not differ significantly. The volume of distribution 
of heptabarbital, which was used as reference compound in each animal, 
was significantly smaller. Since the apparent volumes of distribution of 
the homologous series are very similar, the difference in half-life among 
the members of the series can be attributed to differences in clearance. 
The clearance constants of elimination are presented in Table 11.3. A 
gradual increase in clearance is seen from the propyl to the heptyl 
derivative. 
The isolated perfused rat liver 
In Figure 11.2 some examples of blood concentration-time curves in this 
system are presented. The curves are clearly monophasic. This is in con-
trast with the type of curves observed after in vivo intravenous admini-
stration. A measurable distribution phase could not be distinguished. 
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cone ( í jgr / l blood; log scale) 
200-
100-
50-
20-
1 0 , 
5-
\ 
" " Ч . 
heptabarbital 
12000 Ajgr 
• * » ^ 
100-
50-
200 
100-
50-
20-
10-
5-
^ Ч 
v. 
5-ethyl-5-heptyl 
barbituric acid 
12000 xigr 
10 20 30 40 50 60 
5-ethyl-5-hexyl 
barbituric acid 
15000 мдг 
5-ethyl-5-pentyl 
barbituric acid 
15000 i igr 
10 20 30 40 50 60 70 80 
Fig. l l . l Blood concentration-time curves of some S-ethyl-5-alkyl sub­
stituted barbiturates following intravenous administration in 
the same rat. The half-life or clearance of heptabarbital was 
used as parameter for the drug metabolic activity of the animal 
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TABLE 11.2 
Hal f- l ives and apparent volumes of d i s t r i b u t i o n of some b a r b i t u r a t e s 
in the i n t a c t r a t and the i s o l a t e d perfused r a t l i v e r system 
Compound H a l f - l i f e (min) H a l f - l i f e r a t i o Apparent volume of 
d i s t r i b u t i o n (ml) 
i n t a c t r a t perfusion i n t a c t r a t perfusion i n t a c t r a t perfusion 
Propyl 
Butyl 
Pentyl 
s-Pent 
i-Pent 
Dm-but 
Hexyl 
Heptyl 
Octyl 
Nonyl 
Hepta 
574+83 
210+37 
48+10 
53+ 9 
39+ 9 
32+ 4 
19+ 4 
15+ 2 
14+ 3 
(2) 
(6) 
(6) 
(4) 
(4) 
(4) 
(5) 
(5) 
(14) 
1249+151 
149+ 
48+ 
32+ 
18+ 
28+ 
13+ 
13+ 
6+ 
7+ 
13+ 
37 
8 
10 
4 
5 
1 
8 
2 
3 
(2) b 
(5) Ь 
( 5 ) a 
(4) Ь 
(4) b 
( 4 ) a 
(5) b 
(6) a 
(4) 
(4) 
6 (43)a 
50.1+3.6 
12.8+3.0 
3.2+0.7 
4.4+1.9 
3.2+0.5 
2.6+0.5 
1.5+0.5 
0.9+0.2 
302.5+72.8b 
17.0+ 7.4 a 
4.1+ 0.7 a 
5.8+ 0.7 a 
3.6+ 0.4 a 
2.7+ 0.7 a 
1.5+ 0.4 a 
1.0+ 0.1 a 
1.2+ 0.2 
0.8+ 0.1 
226+36 
338+66 
305+33 
286+75 
239+13 
377+97 
250+34 
246+46 
162+30 
221+13 
255+26 
234+11 
228+10 
238+21 
220+12 
241 + 26 
246+31 
275+21 
258+14 
255+21 C 
1) ratio half-life ('derivative/heptabarbital), measured in the same rat or the same perfusion 
2) mean + S. D. ; number of experiments in parentheses 
a. not significantly different Ρ > 0.0S (Student's t-test) 
b. significantly different 0.001 < Ρ < 0.05 
c. significantly different Ρ < 0.001 
cone (iugr/ml perfusate, log scale) -
50-
20 
10-
5-
2-
1-
heptabarbital 
eOOOiJgr 
N. 
X. 
X 10 15 2 0 τ -25 
50-
20-
10-
5-
2-
5-ethyl-5-butyl 
barbituric acid 
"•-^.«^ 8 0 0 0 ugr 
'"·--
5 0 · 
\ 
20 
10-
5-
2-
N 
heptabarbital 
10000 Aigr 
N 
i o 2 0 3 0 4 0 
5-ethyl-5-heptyl 
barbituric acid 
10000 ugr 
30 40 
time ( min) 
Fig. 11.2 Blood concentration-time curves of some eLhyl-alkyl substitut­
ed barbiturates in the isolated perfused rat liver system 
Right: 5-ethylS-heptyl barbituric acid 
Left : 5-ethyl-S-butyl barbituric acid 
The half-life or clearance of heptabarbital was used as para­
meter for the drug metabolic activity of the liver 
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Os TABLE 11.3 
Clearances and clearance ratios of some barbiturates in 
the intact rat and the isolated perfused rat liver system 
Compound Clearance (ml/min) 
3 intact rat perfusion 
Clearance ratio 
intact rat perfusion 
Clearance ratio 
intact rat perfusion 
Propyl 
Butyl 
Pentyl 
s-Pent 
i-Pent 
Dm-but 
Hexyl 
Heptyl 
Octyl 
Nonyl 
0.34+0.09 
1.02+0.26 
4.71+0.99 
3.97+0.53 
4.14+0.78 
8.02+0.90 
10.09+1.94 
13.17+2.55 
(2) 
(6) 
(6) 
(4) 
(4) 
(4) 
(5) 
(5) 
0.14+ 0.03 
1.15+ 0.39 
3.90+ 1.04 
5.92+ 0.93 
10.12+ 2.15 
6.60+ 2.22 
12.30+ 2.16 
17.62+ 9.18 
28.01+14.57 
29.89+12.25 
(2) 
(5) 
(5) 
(4) 
(4) 
(4) 
(5) 
(6) 
(4) 
(4) 
0.026+0.001 
0.123+0.024 
0.488+0.078 
0.276+0.027 
0.413+0.031 
0.530+0.035 
1.167+0.147 
1.586+0.259 
0.004+0 
0.068+0 
0.289+0 
0.161+0 
0.310+0 
0.425+0 
0.809+0 
1.025+0 
1.110+0 
1.611+0 
.oor 
.005h 
.056c 
.023° 
.062b 
.017Ъ 
.065C 
.122Ъ 
.272 
.225 
0.022+0.001 0.005+0.001 
0.105+0.020 0.084+0.003a 
0.418+0.067 0.356+0.069a 
0.237+0.023 0.196+0.024a 
0.354+0.026 0.384+0.078a 
0.454+0.030 0.525+0.021Ъ 
1.360+0.222 1.266+0.151 
1.371+0.336 
1.989+0.276 
a 
Hepta 10.89+3.21 (14) 19.92+ 8.94 (43) 
1) heptabarbital alevance ratio 2) hexyl alearanae vatio 3) mean +_ S.O.; number of experi­
ments in parentheses 
a. not significantly different Ρ > 0.05 
b. significantly different 0.001 < P< 0.05 
c. significantly different P< 0.001 
The half-lives of the perfusion studies are presented in Table 11.2. Some 
of these values are shorter than those found in vivo, while for others 
the difference is not significant. These differences may be caused by 
variation in the metabolic activity of the livers used. The half-life 
ratio, which is independent of such variations, indicates that with the 
exception of the propyl derivative the values found in vivo and in the 
perfusion are very close. There are no large differences in the volume 
of distribution between the members of the series. In contrast with the 
intact rat experiments the volume of distribution of heptabarbital and 
the alkyl derivatives do not differ significantly. The clearance con-
stants and the clearance ratio are presented in Table 11.3. The hepta-
barbital clearance ratio found in the perfusions is lower than that found 
in the intact rat. For some unknown reasons the A value found for hepta-
barbital in the intact rat is much higher than that found for the alkyl 
derivatives resulting in a smaller volume of distribution, as mentioned 
earlier. This means that the clearance constant found for heptabarbital 
in vivo is rather low (eq. 4) and the resulting heptabarbital clearance 
ratio is therefore high. The discrepancy between the clearance ratio in 
vivo and in vitro is not present when another barbiturate of the series, 
p.e. the hexyl derivative, is used as reference compound (Table 11.3). 
Partition coefficients 
The octanol/water and the hepatocytes/water partition coefficients are 
presented in Table 11.1. The observed values for the octanol/water TPC 
are in good agreement with those calculated by Hansch (1967). When the 
APC,7 ,. values of the two partition systems are compared, a good cor-
relation was found (r 0.959, s 0.255). In both partition systems there 
is an increase in the values for derivatives possessing more carbon atoms 
in the side chain. A derivative with a straight substituent seems to be 
more lipophilic than the one with a branched side chain having the same 
number of carbon atoms. According to Hansch (1973), a parabolic relation-
ship has to be expected between the rate of elimination and the partition 
coefficient. Figure 11.3 presents a fitted curve showing the relationship 
between the heptabarbital clearance ratio and the octanol/water partition 
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coefficient. The correlation coefficient and standard deviation are 
respectively 0.977 and 0.134 (0.929 and 0.222 for the hepatocytes/water 
partition coefficient). When the half-life ratio is used as biological 
response the correlation values were for the octanol/water and hepato­
cytes/water system respectively r 0.968, s 0.096 and r 0.950, s 0.280. 
0.5--
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ϋ 
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о 
-го-
го 1.5 2.0 25 30 35 40 
log (Ρ- octanol ) 
Fig. 11.3 Relationship between log к- -, (rel) heptabarbital (у) and 
log P-ootanol (x) desoribeaby α ραχκώοΐίο function 
(y - cutfi + bx + a) 
О vivo A perfusion 
Sleeping time and blood concentration at awakening 
In order to investigate whether differences exist in central depressant 
potency among the members of the series, blood concentrations at awaken­
ing were measured. These concentrations were deduced from the blood con­
centration-time curves by measuring the sleeping time. The sleeping time 
and the corresponding blood concentrations at awakening are given in 
Table 11.4. The duration of sleeping time was dose-dependent. The blood 
concentrations at awakening were, however, dose-independent and rather 
constant for the various barbiturates. Reports from the literature con-
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TABLE П . 4 
Sleeping times (A,min) and blood concentrat ions at awakening (B.min) of a number of 
5-ethyl-5-alkyl s u b s t i t u t e d b a r b i t u r a t e s following intravenous admini s t ra t ion (12 mg) in r a t s 
Butyl Pentyl s-Pent i-Pent Dmrbut Hexyl Heptyl 
A B A B A B A B A B A B A B 
10 
12 
40 
552 
2 
128 
1502 
33 
37 
46 
31 
38 
34 
21 
27 
32 
47 
502 
24 
21 
22 
21 
18 
42 
50 
1122 
15 
16 
13 
за
1 
BS1 
95 
21 
22 
17 
27 
37 
41 
69 
14 
20 
18 
19 
20 
20 
36 
272 
282 
14 
16 
15 
11 
17 
15 
16 
19 
20 
272 
12 
15 
15 
10 
11 
Mean B 3 36 + 5 2 1 + 2 15 + 1 20 + 3 1 8 + 3 15 + 2 13 + 2 
1) dose 10 mg 
2) dose IS mg 
3) significantly different (F-test; F(6 22)= 37.90) 
vo 
ceming blood concentrations at awakening in rats are mainly restricted 
to barbital and pentobarbital. Our value for the latter is in good agree-
ment with that reported by Kato (1967). 
Starting from the butyl derivative to the heptyl derivative there 
is a decrease in blood concentration at awakening. The propyl derivative 
possesses only a weak hypnotic potency, which is in agreement with the 
finding of Exley (1954) in mice. The anaesthetic potency was only 41% of 
amobarbital. 
DISCUSSION 
The usefulness of the relative clearance constants for kinetic studies 
appears from the smaller relative errors, when compared with the absolute 
values. For the perfusion studies the relative error ranges from 15 to 52 
per cent., while for the clearance ratio the error has been reduced to 
4-24 per cent. Heptabarbital possesses various properties which make it 
a suitable reference compound, particulary for in vitro studies, as has 
been pointed out in chapter 5. Nevertheless, there is also a disadvantage 
in the use of this barbiturate as a reference as appears from the dif-
ferences in the heptabarbital clearance ratio found in vivo and in the 
perfusions. However, this can be corrected easily and it plays no role 
when the barbituric acid derivatives are compared either in the intact 
animal or in the isolated rat liver perfusion system. 
The majority of reports on the metabolism and elimination of barbi-
turates in rats are restricted to the ethyl and to the s-pentyl substitut-
ed derivatives. Our values found for the s-pentyl derivative in the intact 
rat are in agreement with those found by Alvarez (1973). However, his 
values which were found in the liver perfusion, using a perfusate volume 
of 100 ml, differ considerably from our values. When a comparison is made 
between the half-lives found by Alvarez in vivo and in vitro the latter 
values are too low considering the volume of distribution. Since the ap-
parent volume of distribution in the perfusion is about twice as small as 
in the intact rat one would expect that the half-life in the perfusion 
would be half the value found in vivo. In vivo there is obviously an equi-
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librium between the binding to blood components as plasma proteins and 
erythrocytes and the binding to other tissues as liver, brain and kidney. 
The apparent volume of distribution, calculated from whole blood levels, 
will be, therefore, in the same order of magnitude for the various bar-
biturates. From the studies of Goldbaum (1954) it appears that with in-
creasing lipophilicity both the fraction bound to the blood components 
and the fraction bound to the other tissues increase too. 
The same holds true for the apparent volume of distribution in the 
perfusion studies. According to the affinity towards hepatocytes (see 
Table 11.1) from the propyl towards the nonyl derivative, an increasing 
uptake by the liver has to be expected, resulting in a growing apparent 
volume of distribution. Our data, however, indicate that the effect of 
this uptake on the apparent volume of distribution is countered by bind-
ing to the perfusate components. This is supported by the studies of 
Jähnchen (1971) with chlorpromazine and promazine, which are reported to 
be bound to the erythrocytes of the perfusate up to 77 and 69 per cent. 
respectively. 
Comparison of the clearance constant and half-life ratio measured in 
the intact rat and in the perfusion studies shows that, with the excep-
tion of the propyl derivative, the ratio is very similar. This indicates 
that for these barbiturates hepatic metabolism is the main route of eli-
mination. This is in accord with the data in the literature dealing with 
urinary excretion of barbiturates. According to Buttar (1974) rats ex-
crete only 0.6% of the administered dose of pentobarbital. Studies on the 
metabolism of 5-ethyl-5-alkyl substituted barbiturates in dogs showed that 
starting from the butyl to the hexyl derivative the barbiturates are 
metabolized almost completely and are excreted unchanged in the urine 
only to a minor extent. Taking into account the much shorter half-life 
of barbiturates in rats, we can assume that in rats too urinary excretion 
of these derivatives is negligible. 
From our data we can conclude that the propyl derivative resembles 
the ethyl derivative, which is reported to be excreted largely in the 
urine of dogs (Ciotti, 1951). The data presented in Table 11.1 and 11.3 
show that there exists a relationship between the rate of elimination and 
the lipophilicity. We have fitted the data to a parabolic function after 
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Hansch (1973) and found a high correlation. As is the problem in most 
cases concerning parabolic correlations the data points cover only the 
left side of the parabola. As long as points are not obtained at the 
other side the parabolic relationship is rather speculative, in spite of 
the high correlation coefficients found. Attempts at fitting the data, 
for instance to a hyperbolic function, result in similar correlation co­
efficients (see Fig. 11.4). 
0.5 
ι г 
3.5 4.0 
log (P-octanol) 
Fig. 11.4 Relationship between log k-.* (vel), heptabarbital (y) and 
log P-ootanol (x) desoribeaby a hyperbolic function 
(y = A. (x-B)/(x+C) 
r = 0.979 s = 0.138 
О vivo A perfusion 
In our studies we increased lipophilicity by introducing larger 
substituents; but it is not unlikely that stereo-chemical rather than 
physico-chemical parameters cause the flattening of the curve presented 
in Figs. 11.1 and 11.3. It is, therefore, obviously of interest to in­
vestigate the effect of increasing the length of the substituents and the 
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lipophilicity on the barbiturate-microsomal enzyme interaction (see 
chapter 16). 
Other important parameters for the biological response are the dis-
tribution in the brain and the hypnotic potency of the compounds. Blood 
concentration of the drug at awakening was found to correspond well with 
the concentration in the brain at that time (Prioux-Guyonnoneau, 1974; 
Smith, 1961). Autoradiographic studies on the distribution of barbiturates 
in the brain showed that the barbiturates do not localize in any specific 
part of the brain. They are rather uniformly distributed throughout the 
various brain areas (Domek, 1960; Lai, 1964). The differences found in 
blood concentration at awakening, therefore, suggest that in addition to 
a difference in hypnotic potency based on an unequal rate of elimination, 
there also exist differences in the hypnotic potency of the barbiturate 
itself. 
The mechanism of barbiturate action is not completely known, although 
numerous studies have been reported in the literature concerning the mode 
of action of barbiturates. Many barbiturates can produce excitatory as 
well as depressant effects, the ratio being dependent on the chemical 
structure of the substituents. Neuropharmacological investigations in-
dicate an interaction with the synaptic transmission (Richard, 1972), 
while studies at cellular level suggest that the activity of barbiturates 
may be due to an inhibition of NADPH dehydrogenase (Giuditta, 1963). 
Exley (1954) found differences in ganglion-depressant activity among 
series of barbiturates, including some ethyl-alkyl derivatives. An in-
creasing order of activity was found with the following derivatives: 
propyl, s-pentyl, hexyl, butyl, isoarayl and pentyl. There is obviously a 
lack in correlation with the lipophilicity of the compounds. Unequal hyp-
notic potency has been reported for various optical antipodes of barbi-
turates (Breimer, 1973; Buch, 1969; Haley, 1970). This suggests that 
stereo-chemical rather than physico-chemical factors are responsible for 
the differences in the intrinsic hypnotic potency of barbiturates. 
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CHAPTER 12 
5-ALLYL- AND 5-BROMOALLYL-5-ALKYL BARBITU-
RATES IN THE RAT AND IN THE LIVER PERFUSION 
INTRODUCTION 
The 5-allyl and 5-bromoallyl substituted derivatives form a class of 
barbiturates some of which are used frequently. After the discovery of 
the hypnotic properties of the 5-ethyl-5-alkyl substituted barbiturates 
it was found that the introduction of an ethylenic group moiety enhances 
the hypnotic potency. This resulted in the synthesis of barbiturates 
with vinyl, butenyl and especially allyl groups. The allyl substituted 
barbiturates generally appeared to possess a higher hypnotic potency 
than the corresponding ethyl homologues (Nielsen, 1926). Introduction 
of a halogen into the allyl group, usually a bromine atom, increased the 
hypnotic potency (Boedecker, 1928) and led to the development of bromo-
R R 
allyl substituted barbiturates as Noctal (1924), Pernocten (1919) and 
brallobarbital (1953), a component of Vesparax . The metabolism of the 
5-allyl and 5-bromoallyl derivatives is somewhat different from that of 
the 5-ethyl-5-alkyl series. Compared with the ethyl substituent the 
allyl, and especially the bromoallyl, group is more susceptible to me-
tabolic conversion. 
Miihlhauser (1974) found secodiol as a metabolite of secobarbital 
in dogs in addition to 3-hydroxy-secobarbital, while for Noctal and 
R R 
Pemocton (Boedecker, 1928), Eunarcon (Ravn-Jonsen, 1970) and brallo-
barbital (Keding, 1969) the conversion of the bromoallyl substituent 
into an acetonyl group has been reported. Although the pharmacokinetics 
of some members of the series have been studied intensively in man 
(Clifford, 1974) and in the rabbit (Somani, 1975) as far as known a 
systematic study of these barbiturates has not been reported. 
In the course of our studies on the ethyl-alkyl substituted barbi-
turates we have investigated the derivatives listed in Table 12.1 and 
tried to find the relationship between their pharmacological behaviour 
and chemical structure. 
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TABLE 12. 1 
Chemical s t r u c t u r e , apparent (APC at pH 7.4) and t r u e 
(TPC) p a r t i t i o n coef f ic ients of a number of b a r b i t u r a t e s 
0 R 
V e _ ^ 
R< С N / 
J II 
0 H 
Compound R, R. R pK log TPC log APC log APC 
1 ¿ 3 a 
octanol/water cells/water 
Allo H allyl -C-C=C 7.68 1.43 0.94 -0.02 
Apro H allyl -Ç-C 7.90 1.61 1.22 0.17 
С 
Tal H allyl -Ç-C-C 7.91 1.76 1.35 0.22 
С 
Ç 
Neal H allyl -C-Ç-C 7.72 2.53 1.71 0.40 
С 
Seco H allyl -Ç-C-C-C 7.90 2.59 1.97 0.54 
С 
Bral H bromo-allyl -C-C=C 7.70 2.05 1.37 0.27 
Noct H bromo-allyl -Ç-C 7.70 2.21 1.47 0.28 
С 
Pern H bromo-allyl -Ç-C-C 7.70 2.58 1.72 0.53 
С 
Reet H bromo-allyl -Ç-C-C-C 7.70 3.13 2.09 0.70 
С 
m-Bral CH3 bromo-allyl -C-C-C 7.90 2.34 1.78 0.66 
Fuñare CH bromo-allyl -C-C 7.90 2.78 2.11 
J
 С 
0.75 
m-Pem CH bromo-allyl -C-C-C 7.90 3.20 2.43 0.87 
Ò 
1) From Doornbos (1969) and Krahl (1940) 
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Fig. 12.1 Blood aanoentration-time ovrves of some 5-allyl-S-alkyl· and 
S-bromoallyl-alkyl substituted barbiturates following intra­
venous administration in the same rat. The half-life or 
alearanae of heptabarbital was used as parameter for the drug 
metabolic activity of the animal 
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Fig. 12.2 Blood conoentration-time curves of some S-bromoallyl-S-alkyl 
substituted barbiturates in the isolated perfused rat liver 
system 
Right: 5-bromoalU/l-5-(l-methylbutyl) barbituric aoid 
(RectidonV 
Left : S-bromoallul-S-d-methylpropryl) barbituric acid 
(Pemocton") 
The half-life or clearance of heptabarbital was used as para­
meter for the drug metabolic activity of the liver 
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RESULTS 
In vivo experiments 
Figure 12,1 shows the blood concentration-time curves of some derivatives 
following intravenous administration in the same rat. The clearance of 
heptabarbital was used as reference for the metabolic activity of the 
animal. In observing the last phase of the curves, which represent the 
overall elimination of the barbiturates, two distinct features can be 
seen. In the first place the rate at which the barbiturates disappear 
from the blood is higher for the derivatives with the larger substituent. 
Secondly, the bromoallyl substituted barbiturate has a shorter half-life 
than the allyl homologue. In Table 12.2 the half-lives and apparent 
volumes of distribution of the barbiturates studied are presented. The 
half-life value of 5 h in rats reported by Pelkonen (1973) for aprobar-
bital is in good agreement with our findings. Unfortunately there are no 
reports available on the half-lives of the other barbiturates. 
There appears to be no structure-correlated differences among 
members of the allyl on the one hand and bromoallyl series on the other 
hand as far as the apparent volumes of distribution are concerned. This 
indicates that the differences in half-life of these barbiturates are 
based on differences in elimination clearances. In Table 12.3 the ab-
solute and relative clearances are presented both for the allyl and 
bromoallyl series. With the exception of nealbarbital, there is an in-
crease in clearance when the alkyl side chain becomes longer. This is 
in agreement with the results obtained in the ethyl-alkyl series. 
The isolated perfused rat liver system 
Apparently the time course of the barbiturates in the isolated perfused 
rat liver system can be described by a one-exponential equation, since 
there is no measurable distribution phase (Fig. 12.2). There is no con-
siderable uptake of barbiturates by the liver, as appears from the ap-
parent volumes of distribution, which equal almost the volume of the 
perfusion fluid (Table 12.2). The half-lives of the derivatives pre-
sented in Table 12.2 show for some compounds considerable differences 
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TABLE 12.2 
Hal f- l ives and apparent volumes of d i s t r i b u t i o n of some b a r b i t u r a t e s 
in the i n t a c t r a t and in the i s o l a t e d perfused r a t l i v e r system 
Compound H a l f - l i f e (min) H a l f - l i f e r a t i o Apparent volume of 
d i s t r i b u t i o n (ml) 
i n t a c t r a t perfusion i n t a c t r a t perfusion i n t a c t r a t perfusion 
Apro 
Tal 
Neal 
Seco 
Bral 
Noct 
Pern 
Reet 
M-bral 
Eunarc 
M-pern 
Hepta 
353+27 
240+34 
294+30 
55+16 
189+22 
163+40 
48+12 
20+ 7 
41+6 
11+ 2 
(3) 
(4) 
(3) 
(4) 
(4) 
(4) 
(3) 
(5) 
(3) 
(24) 
235+78 
113+19 
120+11 
32+13 
230+45 
128+39 
32+10 
12+ 5 
27+ 4 
18+ 4 
7+ 1 
(3) b 
(3) b 
(3) C 
(3) a 
(5) a 
( 3 ) a 
(3) a 
(4) Ь 
(3) Ь 
(3) 
(3) 
9+ 3 (34)b 
26.3+3.2 
19.6+3.3 
25.1+1.9 
5.0+1.4 
14.6+1.5 
13.2+1.5 
4.0+0.8 
1.8+0.3 
3.7+0.9 
76.5+32.4b 
19.6+ 
22.1 + 
3.2+ 
28.8+ 
20.1 + 
3.7+ 
1.0+ 
5.4+ 
1.9+ 
1.6+ 
3.5a 
4.5a 
0.4a 
3.9e 
2.5b 
0.4a 
o.ib 
1.4a 
0.2 
0.1 
291+14 
281+34 
247+27 
242+85 
249+51 
204+54 
207+36 
279+48 
295+14 
161+41 
242+18 
273+28 
202+13 
226+16 
263+27 
220+30 
202+ 8 
192+18 
269+50 
230+12 
221+17 
226+30c 
1) ratio half-l-ife (derivative/heptabarbital), measured in the same rat or the seme perfusion 
2) mean + S. D. ; number of experiments in parentheses 
a. not significantly different Ρ > 0.05 о. significantly different Ρ < 0.001 
X¿ Ъ. significantly different 0.001 < Ρ < 0.05 
TABLE 12.3 
Clearances and clearance ratios of some barbiturates in 
the intact rat and the isolated perfused rat liver system 
Compound Clearance (ml/min) Clearance ratio Clearance ratio 
Apro 
T a l 
Neal 
Seco 
Bral 
Noct 
Pern 
Reet 
M-bral 
Eunarc 
M-pem 
i n t a c t r a t 
0.58+0.08 
0.84+0.10 
0.62+0.09 
3.14+0.45 
0.95+0.21 
1.05+0.13 
3.20+0.60 
12.29+2.14 
5.56+1.12 
(3) 
(4) 
(3) 
(4) 
(4) 
(4) 
(3) 
(5) 
(3) 
perfusion 
0.67+0.11 
1.72+0.48 
1.28+0.20 
5.76+2.72 
0.76+0.29 
1.26+0.47 
4.86+1.81 
13.12+4.45 
6.97+0.80 
8.11+0.75 
23.33+3+34 
( 3 ) a 
( 3 ) b 
( 3 ) b 
( 4 ) a 
( 5 ) a 
( 3 ) a 
( 3 ) a 
( 4 ) a 
( 3 ) a 
(3) 
(3) 
i n t a c t r a t 
0.048+0.002 
0.058+0.010 
0.044+0.006 
0.211+0.028 
0.116+0.006 
0.099+0.008 
0.222+0.026 
0.770+0.024 
0.603+0.051 
perfusion 
0.015+0.005° 
0.066+0.006 a 
0.049+0.007 a 
0.30 3+0.064 b 
0.037+0.005 e 
0.047+0.004° 
0.314+0.030 b 
0.965+0.175 
0.2 70+0 ..ОбО0 
0.524+0.042 
i n t a c t r a t 
0.063+0.003 
0.075+0.013 
0.056+0.008 
0.274+0.036 
0. 150+0.008 
0.128+0.011 
0.288+0.034 
0.782+0.067 
perfusion 
0.016+0.005° 
0.068+0.007 a 
0.051+0.007 a 
0.335+0.066 a 
0.038+0.005° 
0.048+0.004° 
0.325+0.03 I a 
0.280+0.062° 
0.544+0.066 
0.616+0.038 
Hepta 12.68+3.01 (24) 22.70+9.80 (24)° 
_ 
1) heptabarbital clearance vatio 2) Reotidon alearanae ratio 
a. not significantly different Ρ > 0.0S 
b. significantly different 0.001 < P< 0.05 
a. significantly different Ρ < 0. 001 
3) mean +_ S.D.; number of 
experiments in parentheses 
with the values found in vivo. The differences may be based in some 
cases on differences in the metabolic activity between the rat and the 
perfused liver and then the half-life ratio found гп vivo and in vitro 
will be similar. The half-life ratios suggest that a difference exists 
between the in vivo and in vitro value for aprobarbital, Noctal and 
brallobarbital. The clearance constants, which can be considered as 
metabolic clearance constants in the isolated perfused rat liver system, 
R 
are shown in Table 12.3. Aprobarbital, Noctal , brallobarbital and its 
N-methyl derivative clearly possess a lower clearance ratio in the liver 
perfusion than in the intact rat. 
Partition ooeffiaienta 
As in the ethyl-alkyl series, the partition coefficients were determined 
in two partition systems, namely the commonly used system octanol/water 
and the isolated hepatocytes/water system. The results are presented in 
Table 12.1. Comparing the APC values at pH 7.4 of the two systems a good 
correlation was found (r 0.936, s 0.088). 
There are apparently three ways to increase the lipophilicity. 
First there is an increase in partition coefficients resulting from the 
introduction of longer alkyl side chain as observed previously in the 
5-ethyl-5-alkyl series. Secondly, substitution of a bromoallyl instead 
of an allyl group has the same effect and finally, a more lipophilic 
barbiturate can be obtained by the introduction of a methyl group to 
the nitrogen of the barbituric acid nucleus. 
Relationship clearance - lipo-philiaity 
As for the 5-ethyl-5-alkyl series we have fitted the clearance ratios to 
the partition coefficients using a parabolic equation. When we excluded 
the data obtained for aprobarbital in vivo and the aberrant in vitro 
values in the bromoallyl series, we found a good correlation. The cor­
relation coefficients and the standard deviation using the octanol and 
the hepatocytes system were respectively r 0.964, s 0.147 and r 0.944, 
s 0.171. 
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TABLE 12.4 
Sleeping times (A,min) and blood concentra t ions at awakening (B.min) of a number of 5-a l ly l-5-a lky l 
and 5-bromoallyl-5-alkyl s u b s t i t u t e d b a r b i t u r a t e s following intravenous a d m i n i s t r a t i o n (12 mg) in r a t s 
Apro Tal Seco Bral Noct Pern Reet 
A B A B A B A B A B A B A B 
63 
74 
75 
36 
44 
43 
155 1 
27 
27 
28 
23 
28 
100 
95 
51 
9 
10 
12 
15 
62 ' 
581 
6 
47 
33 
44 
44 
35 
45 
50 
29 
33 
32 
31 
37 
59 
50 
10 
18 
23 
20 
25 ' 
16 
20 
30 1 
11 
11 
17 
11 
Mean В 2 4 1 + 2 2 6 + 3 1 0 + 2 4 0 + 5 3 3 + 2 2 0 + 1 1 3 + 3 
1) dose 15 mg 
2) significantly different (F-test; F(5 15j= 28.73) 
Sleeping time and blood oanaentvatian at awakening 
Differences in central depressant potency can be investigated roughly by 
measuring the brain drug concentration at awakening assuming a uniform 
drug distribution through the brain. The blood concentration at that 
time corresponds well with the brain drug concentration. We have, there-
fore, determined that blood concentration with the help of the sleeping 
time and the blood concentration-time curves. The results are presented 
in Table 12.4. It can be seen that in this series too the derivative 
with the 1-methyl-butyl substituent, secobarbital, has the lowest value 
for the concentration at awakening. 
DISCUSSION 
There is no clear structure-related difference in the apparent volume 
of distribution between the members of the 5-allyl and 5-bromoallyl 
series. The differences in half-life apparently reflect differences in 
clearances. Here too the discrepancy between the heptabarbital ratio 
found in vivo and in vitvo is present as mentioned earlier for the 5-
D 
-ethyl-5-alkyl series. The use of Rectidon as reference compound can 
avoid these apparent discrepancies. Observing the clearance constants 
found for the allyl substituted derivatives a progressive enhancement 
in clearance is seen for compounds with longer alkyl substituents, with 
the exception of nealbarbital. Metabolism of alkyl substituted barbi-
turates occurs mainly by hydroxylation at the penultimate carbon atom 
of the longest side chain (Maynert, 1965). In the neopentyl side chain 
this carbon atom is blocked, therefore only the allyl substituent, 
which is apparently less susceptible to oxidation, can be metabolized. 
This is confirmed by studies on nealbarbital in which as principal me-
tabolite nealbarbital diol was found (Gilbert, 1974). A similar effect 
has been reported by Dixit (1969), who increased the duration of action 
of amobarbital in mice by two-fold by blocking the penultimate carbon 
atom by the introduction of a methyl group. By comparing the clearance 
constant ratios in vivo and in the perfusion it can be seen that a sig-
83 
nifleant difference exists with aprobarbital. In dog and man aprobarbi-
tal is excreted unchanged in the urine in amounts up to 24% of the dose 
administered (Maynert, 1949). In the intact rat the clearance constant 
of elimination of aprobarbital is probably representing the renal 
clearance constant. Renal excretion of aprobarbital is facilitated by 
its rather low lipophilicity. Nealbarbital, which is also metabolized 
slowly, but which is more lipophilic, is not excreted by the kidney 
Gilbert, 1974). The difference in clearance ratio found in vivo and in 
the perfusion for some 5-bromoallyl substituted derivatives cannot be 
R due to renal excretion. Noctal and brallobarbital are reported to 
appear unchanged in the urine of man in negligible amounts (Keding, 
1969; Maynert, 1949). 
In an extensive study on the pharmacokinetics of brallobarbital it 
was found that the rate of elimination depends on the route of admini-
stration. Presenting this barbiturate directly to the liver resulted in 
D 
an increase in the half-life (Yih, 1976). Toxic effects of Noctal in 
rats have been reported resulting in so-called delayed death, while for 
R R 
Pemocton and Rectidon a lower toxicity was reported (Hoick, 1936). 
Obviously, the metabolic pathway of the bromoallyl group is involved in 
R R 
this phenomenon. With Pemocton and Rectidon hydroxylation at the 
alkyl substituent will become more dominant; considering their meta-
bolism these barbiturates belong to the allyl series. The N-methylated 
derivatives are cleared more rapidly than their non-methylated homologues. 
Demethylation, therefore, would lead to accumulation of the nor-compound. 
In spite of reports on demethylation of N-methyl derivatives (Craig, 1970) 
we never found demethylation products in the intact rat and in the per-
fusion studies. This is in agreement with reports on the metabolism of 
Eunarcon (Ravn-Jonsen, 1974) and more recent studies on the metabolism 
of 1-N-methyl-barbital (Vore, 1975), which indicate that dealkylation is 
a minor route of elimination in the rat. Therefore, the higher clearance 
of the methylated derivatives is the result of the higher lipophilicity 
of these compounds. Possibly, this increase in lipophilicity results in 
a higher affinity of the compounds to the microsomal enzymes. For the 
bromoallyl derivatives on the one hand the higher lipophilicity may re-
sult in a higher clearance, while on the other hand bromination of the 
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allyl group will result in a substituent, which is much more susceptible 
to metabolism and is also faster eliminated. 
The results presented in Table 12.4 show that the bromoallyl deri-
vatives possess a higher central depressant potency than the allyl deri-
vatives. This effect, however, is opposed by the increased metabolism of 
those compoundb. In conclusion, it can be stated that the earlier con-
cept of increased hypnotic action by the introduction of a bromine is 
questionable. Moreover, bromination enhances the toxicity of some deri-
R 
vatives as has already been found for Noctal and brallobarbital. 
85 
CHAPTER 13 
RING-SUBSTITUTED BARBITURATES IN THE RAT AND IN THE LIVER PERFUSION 
INTRODUCTION 
The ring-substituted barbiturates represent a series of barbituric acid 
R 
derivatives most commonly used in medical practice. Cyclopal , cyclo-
R . R 
barbital-Ca (Phanodorm ) and heptabarbital (Medomin ) are employed as 
hypnotics, while phénobarbital (Luminal ) and N-methylphenobarbital 
R (Prominal ) are used as sedatives and anti-epileptic drugs (Blum, 1932). 
Until recently hexobarbital (Evipan ) has been employed as an anaesthe-
tic. Moreover, hexobarbital has been used widely as a model substrate 
for studying the hydroxylating activity of the liver, either by measur-
ing sleeping times or disappearance rate of hexobarbital. 
The metabolic fate of these barbiturates has been investigated in-
tensively. A series of papers dealing with the metabolism of hexobarbi-
tal in rabbits has been published by Tsukamoto (1958), followed by re-
ports on the metabolism of cyclobarbital. Studies in rats and dogs have 
been carried out by Hoicomb (1974) and Bush (1973) respectively. 
The cycloalkenyl substituted barbiturates have been reported to be 
hydroxylated in the cyclic substituent preferably at the 3-position and 
they can be converted into ketones (Nielsen, 1968). For methylphenobar-
bital the 4-hydroxy-phenyl derivative has been reported as principal 
metabolite (Mark, 1963). 
The pharmacokinetics in man of some members of the series have been 
studied recently (Breimer, 1974; Clifford, 1974), but a study on the 
structure-activity relationship (SAR) of a large number of this type of 
barbiturates has not yet been undertaken. For this purpose we have syn-
thesized several N-methylated derivatives in addition to hexobarbital 
and methylphenobarbital. 
We have studied the pharmacokinetics of some cyclic substituted 
barbiturates, the chemical structure of which is given in Table 13.1, in 
the intact rat and in the isolated perfused rat liver system. We have 
tried to find a relationship between their physico-chemical characteris-
86 
TABLE 13. 1 
Chemical s t r u c t u r e , apparent (APC at pH 7.4) and true 
(TPC) p a r t i t i o n coef f ic ients of a number of b a r b i t u r a t e s 
0 
η 
«1 
Λ 
•Ν' 
Η 
c=o 
Compound R R. pK log TPC log APC log APC 
octanol/water cells/water 
Norhexo 
Cyclop 
Cyclo 
Hep ta 
Rep 
m-Cyclop 
Hexo 
m-Cyclo 
m-Pheno 
m-Hepta 
m-Rep 
H 
H 
H 
H 
H 
с н
з 
C H3 
C H3 
сн3 
CH3 
снз 
-с 
-c-c=c 
-C-C 
-C-C 
-C-C 
-с-с=с 
-с 
-C-C 
-C-C 
-C-C 
-C-C 
4 > 
-< 
< > 
4 ) 
κ ι 
"Л i 
-< 
ч > 
ч > 
ч > 
Ч ) 
Ч ! 
7.86 1.16 1.02 0.08 
7.80 1.64 1.51 0.22 
7.51 2.02 1.77 0.27 
7.45 2.45 2.17 0.48 
7.52 2.78 2.53 0.57 
8.26 1.95 1.89 0.41 
8.20 2.04 1.98 0.49 
8.14 2.32 2.25 0.63 
7.70 2.03 1.86 0.48 
7.85 2.95 2.82 0.78 
7.92 3.26 3.15 1.13 
1) From Butler (1952); Doornbos (1969) and Kakemi (1967) 
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tics and their pharmacokinetic behaviour. 
RESULTS 
In vivo experiments 
In Figure 13.1 blood concentration-time curves are shown following in­
travenous administration in the same rat. The curves display the same 
biphasic time courses as was found earlier after intravenous injection 
(chapters II and 12). The rate at which these four barbiturates dis­
appear from the blood seems to be connected with the chemical structure 
cone ( jugr/ml blood; log scale) 
0 0 : 
5 0 -
2 0 -
10, 
1 
5 -
heptabarbital 
i 1 2 0 0 0 iigr 
• 
\ 4 
— 1 1 1—ι 1—r*-i 1 1—ι 1—г-
1 0 0 
5 0 
20-
10-
5-
'\ 
hexobarbital 
1 2 0 0 0 ugr 
V. 
•ч. 
- ι 1 — ι — ι 1—г^—ι 1 1 — ι — ι — | -
2 0 4 0 6 0 С 100 120 
2 0 0 -
norhexobarbital 
10 0 0 0 i jgr 
cyclobarbital 
1 0 0 0 0 Aigr 
— ι — • — ι — ι — ι — ι — ι — ι — ι — ι — ι — г 
2 0 4 0 6 0 0 1 0 0 120 
time ( mm) 
Fig. 13.1 Blood-coneentraticn-time curves of some oycloalkenyl substi­
tuted barbiturates following intravenous administration in the 
same rat. The half-life or clearance of heptabarbital was used 
as parameter for the drug metabolic activity of the animal 
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TABLE 13.2 
Half-lives and apparent volumes of distribution of some barbiturates 
in the intact rat and the isolated perfused rat liver system 
Compound 
Norhexobarbital 
CyclopalR 
Cyclobarbital 
Heptabarbital 
Reposal 
Methylcyclopal 
Hexobarbital 
Methylcyclobarbital 
Methylphenobarbital 
Methylheptabarbital 
Methylreposal 
intact 
78+13 
75+ 7 
50+12 
17+ 6 
18+ 4 
26+ 3 
33+13 
10+ 2 
Half-life 
:rat 2 
( 7) 
( 5) 
( 5) 
(14) 
( 4) 
( 4) 
( 7) 
( 3) 
(min) 
perfusion 
108+21 
59+ 5 
25+ 4 
7 + 2 
9+ 1 
10+ 1 
7+ 2 
4+ 1 
146+16 
2+ 1 
3+ 1 
( 3 ) a 
(3) b 
( 3 ) b 
(32)c 
( 3) 
(3) b 
( 4 ) C 
( 4 ) c 
( 3) 
( 3 ) C 
( 3) 
Half-life 
intact rat 
5.6+2.2 
4.2+1.6 
2.9+1.1 
1.4+0.3 
1.3+0.5 
2.0+0.5 
0.8+0.1 
ratio 
perfusion 
11.8+2.7b 
8.7+1.3b 
4.6+0.9b 
1.4+0.2 
1.5+0.3a 
l.l+0.2a 
0.6+0.Ie 
16.6+3.2 
0.4+0.lb 
0.4+0.1 
Apparent 
distribut 
intact rat 
171+222 
313+101 
291+105 
197+ 55 
263+ 46 
266+ 31 
895+282 
187+ 43 
volume of 
ion (ml) 
perfusion 
252+28 
230+43 
226+29 
242+19b 
220+ 9 
256+43 
228+21 
249+22 
222+15 
212+10 
221+16 
oo 
1) ratio half-life (derivative/heptabarbital), measured in the same rat or the same perfusion 
2) mean + S.D.; number of experiments in parentheses 
a. not significantly different Ρ > 0.05 (Student's t-test) 
b. significantly different 0. 001 < Ρ < 0.05 
c. significantly different P< 0.001 
о TABLE 13.3 
Clearances and clearance ratios of some barbiturates in 
the intact rat and the isolated perfused rat liver system 
Compound 
intact rat 
Clearance (ml/nin) 
2 
perfusion 
Clearance 
intact rat 
ratio 
perfusion 
Norhexobarbital 
Cyclopal 
Cyclobarbital 
Heptabarbital 
Reposal 
Methylcyclopal 
Hexobarbital 
Methylcyclobarbital 
Methylphenobarbital 
Me thy Ihe ρ t abarbi tal 
Methylreposal 
I .39+ 0 .25 ( 7) 
3.21+ I .66 ( 5) 
A.Sójf 1.90 ( 5) 
12.21+ 2 .82 (14) 
15.01+ 4 .76 ( 4) 
14.53+ 3 .57 ( 4) 
22 .32+ 6 .69 ( 7) 
19 .48+12 .58 ( 3) 
1.53+ 0 . 4 4 ( 3) 
2.И1+ 0 . 6 8 ( 3 ) a 
7.96+ 0 . 7 2 ( 3 ) Ъ 
21.82+ 5 .81 ( 3 2 ) C 
1 7 . 5 5 + 0 . 6 5 ( 3) 
17.80+ 4 . 4 9 ( 3 ) a 
3 2 . J 7 + 1 1 . 6 5 ( 4 ) b 
4 6 . 5 1 + 1 3 . 3 9 ( 4 ) c 
1.29+ 0 . 2 4 ( 3) 
57.67+ 4 .19 ( 3 ) b 
52.61+ 6 . 9 6 ( 3) 
0 . 1 3 2 + 0 . 0 1 4 
0 . 2 7 7 + 0 . 0 7 3 
0 . 3 5 9 + 0 . 0 7 2 
1.0 72+0.205 
1.331+0.316 
2 . 0 1 9 + 0 . 0 7 7 
1.676+0.723 
0 . 0 9 2 + 0 . 0 0 8 
0 . 134+0.010 b 
0 . 2 9 9 + 0 . 0 : 8 b 
0 . 7 5 7 + 0 . 0 6 3 
0 . 8 1 5 + 0 . 0 9 2 a 
I . 2 5 2 + 0 . 0 5 4 a 
1.554+0.208° 
0 . 0 7 6 + 0 . 0 0 9 
2 . 5 7 0 + 0 . 3 0 1 a 
2 . 4 2 8 + 0 . 4 1 4 
1) heptabarbital clearance ratio measured in the same rat or the same perfusion 
2) mean +_ S.D.; number of experiments in parentheses 
a. not significantly different P> 0.0S (Student's t-test) 
b. significantly different 0.001 < P< 0.05 
a. significantly different P< 0.001 
and can be summarized as follows: the cycloheptenyl derivative dis-
appears more rapidly from the blood than the cyclohexenyl substituted 
compound; N-methylation increases the disappearance rate; the compound 
with a methyl substituent at the 5-position disappears more slowly from 
the blood than its 5-ethyl substituted homologue. 
In Table 13.2 the absolute and relative half-lives have been given 
together with the apparent volumes of distribution. Our value for the 
hexobarbital half-life is in the same range as that reported by Holcomb 
(1974). Unfortunately there are no reference data available for the 
other compounds. 
The apparent volumes of distribution were subject to a considerable 
variation. No immediate explanation can be given for the large apparent 
volume of distribution, found for methylcyclobarbital. 
In Table 13.3 the clearance constants of elimination and the hepta-
barbital clearance ratio are presented. The clearance of the N-methylated 
barbiturates is considerably larger than that of the corresponding parent 
compounds. 
The isolated perfused liver 
Figure 13.2 presents the time courses of some ring-substituted barbitu-
rates in the perfusion system. As was found previously, the time courses 
of the barbituric acid derivatives in this system can be described ap-
parently by a one-exponential equation. However, for the N-methylated 
compounds a biphasic time course has to be expected, since there exist 
considerable differences in clearance for the optical antipodes (Breimer, 
1974). 
The half-lives and apparent volumes of distribution are presented 
in Table 13.2. In contrast with the results found in vivo, the apparent 
volumes of distribution of the derivatives in the perfusions do not dif-
fer much and are of the same order of magnitude as the perfusion volume. 
Hexobarbital is the only compound of which reference data are avail-
able in the literature. Half-lives of about 11 and 7.5 min have been re-
ported by Holcomb (1974) and by Alvarez (1971) respectively. These 
authors, however, used a perfusion volume of 100 ml. 
91 
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Fig. 13.2 Blood aoncentration-time curves of some ayaloalkenyl substi­
tuted barbiturates in the isolated perfused rat liver system 
Right: N-methylheptabarbital 
Left : ayalobarbital 
The half-life or alearanae of heptabarbital was used as para­
meter for the drug metabolic activity of the liver 
The clearance constants and clearance ratios shown in Table 13.3 
are consistent with half-lives presented in Table 13.2 Since there are 
no significant differences in apparent volume of distribution between 
the several members of the series the differences in half-life are due 
to differences in clearance. 
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TABLE 13.4 
Sleeping times (A,min) and blood concentra t ions at awakening (B,mg/1) of a number of cyclo-
alkenyl s u b s t i t u t e d b a r b i t u r a t e s following intravenous a d m i n i s t r a t i o n (12 mg) in r a t s 
Norhexo Cyclop Cyclo Hepta m-Cyclop Hexo m-Cyclo 
A B A B A B A B A B A B A B 
88 
105 
51 
61 
22 
24 
43 
47 
60 
27 
36 
20 
23 
26 
2 
7 
8 
14 
14 
48 
30 
38 
76 
43 
4 
5 
6 
7 
7 
9 
9 
9 
23 
27 
21 
22 
17 
19 
18 
23 
3 
6 
7 
9 
16 
26 
29 
26 
3 
8 
11 
16 
22 
14 
19 
16 
5 
5 
11 
11 
15 
31 
13 
17 
11 
10 
9 
12 
Mean В 2 5 6 + 7 2 6 + 6 3 9 + 7 2 1 + 3 2 4 + 5 1 8 + 4 1 2 + 3 
1) Dose 25 mg 
2) Signifioantly different (F-test) 
Partition coefficients 
Octanol/water and hepatocytes/water partition coefficients are presented 
in Table 13.1. There was a good correlation between the values of the 
two partition systems (r 0.957, s 0.087). The TPC's in both systems are 
lower than expected on basis of the data obtained with the alkyl sub-
stituted barbiturates. Similar results have been reported by Janssen 
(1973) for the partition system comoil/water and by Kakemi (1967). The 
partition coefficient increases with increasing ring size both for the 
N-methyl derivatives and the nor-compounds. The N-methylated derivatives 
are more lipophilic than the corresponding parent compounds. 
Sleeping times and blood eoncentrations at awakening 
In Table 13.4 the sleeping times and the blood concentrations at awaken-
ing have been listed. The value obtained for hexobarbital is in agree-
ment with that reported by Prioux-Guyonneau (1974). Norhexobarbital dis-
played a poor hypnotic activity. Dosages of 12 mg induced sleeping times 
of 3-4 min. 
DISCUSSION 
The clearance ratios, presented in Table 13.3, suggest that there is a 
difference in clearance between the intact rat and the perfusions for 
R 
norhexobarbital, Cyclopal and cyclobarbital, although not so extreme as 
found previously for 5-ethyl-5-propyl barbituric acid (Table 11.3) and 
aprobarbital (Table 12.3). It may be that in the intact animal these 
derivatives are eliminated partly by other routes than hepatic meta-
bolism. This is supported for norhexobarbital by studies in dogs, in 
which was shown that 13 per cent, of the dose was excreted unchanged in 
the urine (Bush, 1953). However, Cyclopal in dogs seemed to be excreted 
only up to 2.5 per cent, of the administered dose (Van der Brook, 1944), 
while the urinary excretion of cyclobarbital in rats has been reported 
to account for 1.5 per cent, of the dose administered (Goldschmidt, 
1959). The clearance ratios of methylcyclopal and hexobarbital found in 
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vivo and in the perfusion show a bettei agreement. Hexobarbital has been 
reported to be eliminated mainly by metabolism and is excreted in the 
urine of rats to a negligible extent (Holcomb, 1974). 
The clearance values found for methylcyclobarbital in the intact 
rat are rather high and are the result of the low blood levels found 
after the distribution phase. First the difference in the rate of elimi-
nation between the methylcyclobarbital enantiomers was thought as origin 
of these low blood levels, the labt part of the curve mainly represent-
ing the elimination of the slow antipode. However, intravenous admini-
stration of (-) methylcyclobarbital in rats resulted also in low blood 
levels. At the moment no ready explanation can be given for the extreme-
ly high apparent volume of distribution of this barbiturate. Therefore, 
when discussing the relationship chemical structure-clearance, we mainly 
restrict ourselves to the data of the perfusion studies. 
Analysing the effect of substituting larger cyclic substituents to 
the barbiturates, one has to keep in mind that besides an enhancement of 
the lipophilicity also the sensitivity of the cyclic substituent may be 
different. This is evident when we compare methylcyclobarbital and 
methylphenobarbital. The size of the cyclic substituent may also play a 
role. 
Both in the N-methyl series and non-methylated series the deriva-
tives with a (bicyclo-3,2,l-oct-2-en-yl) substituent disappear slower 
from the blood than the cycloheptenyl substituted compounds. This is 
consistent with the values reported for the half-lives of heptabarbital 
D 
and Reposal in man being 7.7 and 9.5 h respectively (Breimer, 1974; 
Kessing, 1963). 
The data, found for the cyclohexenyl substituted derivatives, in-
dicate that for these compounds the lipophilicity is the most important 
parameter in determining the rate of metabolism, since for these four 
barbiturates hydroxylation at the 3-position of the ring-substitaent has 
been reported to be the major pathway of metabolism in the rat. In our 
studies with N-methylated barbiturates we could never detect the de-
methylation products, which should accumulate, since they are metabolized 
at a much slower rate. This is confirmed for hexobarbital by the studies 
of Holcomb (1974). Methylphenobarbital, however, has been reported to be 
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demethylated in rats in amounts up to 50 per cent, of the administered 
dose (Butler, 1952; Craig, 1970). Our results suggest that the rapid 
clearance o£ the N-methyl series can be contributed to the higher lipo-
philicity of these barbiturates and not to the existence of an addi-
tional metabolic pathway such as demethylation. 
As in the two other series of barbituric acid derivatives we have 
studied the structure-clearance relationship. Figure 13.3 shows a graph 
of the heptabarbital clearance ratios against the partition coefficients. 
It seems as if the N-methyl and the nor-compounds behave as members of 
R 
two different homologue series, wherein the clearance values of Reposal 
and its N-methyl homologue lie on the descending part of the parabola. 
The majority of the N-methylated derivatives possess a higher central 
depressant potency than the corresponding nor-compounds (Table 13.4). 
However, this is opposed by the higher metabolic clearance. The net 
effect being a short hypnosis. This makes them to potential suitable 
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Fig. 13.3 Graph of the logarithm of the heptabarbital clearance ratio, 
measured in the isolated perfused rat liver system 
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drugs in hypnotic therapy in man, since the risk of residual effects is 
small, as has been shown for hexobarbital (Breimer, 1974). 
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CHAPTER 14 
PHABMACOKINETICS OF BARBITURATES IN THE 
ISOLATED RAT HEPATOCYTE SUSPENSION 
INTRODUCTION 
With the development of new techniques for the enzymatic isolation of 
hepatocytes, it is now possible to obtain large quantities of morpholo-
gical intact and biochemically functional cells. It has been shown that 
in hepatocyte suspensions the rate of oxygen consumption and of gluconeo-
genesis are similar to those observed in the intact organ (Krebs, 1975; 
Quistorff, 1973; Wagle, 1975). 
Isolated hepatocytes have been used successfully in metabolic 
studies with alcohols (Grunnet, 1973; Moldeus, 1974), ethylmorphine 
(Erickson, 1976) and the first pharmacokinetic study in isolated hepato-
cytes using diphenylhydantoin as test substance has been published 
recently (Inaba, 1975). 
In the course of our study on the relationship between the pharmaco-
kinetics of barbiturates in intact rats, liver perfusions and enzyme pre-
parations the isolated intact hepatocytes seem to be an ideal intermediate 
test system, since a number of drugs may be studied simultaneously under 
identical conditions using the same pool of hepatocytes. We, therefore, 
studied the pharmacokinetics of some homologous series of barbiturates 
and compared the results with those of the liver perfusions. 
METHODS 
Rat liver parenchymal cells were isolated according to the methods de-
scribed by Seglen (1973) and Bojar (1975), with slight modifications. 
Liver cell concentrations were quantitated by counting aliquote of the 
suspension in a Bürker-Türk counting chamber to which 0.6% Trypan Blue 
was added. Cell yields ranged from 300 to 500 χ 10 cells per liver, 
about 10% of which was stained with Trypan Blue. 
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Incubations were performed in the system presented in Fig. 6.2. which 
is a modification of the apparatus used by Jeejeebhoy (1975). The composi­
tion of the incubation medium was the following: 5 ml barbiturate solution 
(10 mg/100 ml buffer III), 10 ml erythrocyte-Eagle solution (1:1 v/v) and 
15 ml hepatocyte suspension. 
The final hepatocyte concentration was 2-3 χ 10 cells/ml. The hepa-
tocyte-erythrocyte solution was equilibrated for 20 min before the barbi­
turate solution was added. At various time intervals samples of 0.5 ml 
were taken and transferred to tubes containing 7 ml ether and internal 
standard. 
RESULTS 
Concentration-time curves were made from a series of barbiturates using 
the same pool of hepatocytes and by taking samples of the hepatocyte 
suspension at various periods after administration of a drug (see Fig. 
14.1). A number of 5-ethyl-5-alkyl barbiturates were studied in the 
suspension of hepatocytes from the same liver, while heptabarbital was 
used as a reference drug. Apparently, the elimination in this metabolic 
system is a first order process in accordance with equation 7 for the 
open one-compartment model. In this homologous series the rate of elimina­
tion increases with increasing chain length of the alkyl substituent (see 
Fig. 14.1). The sequence in rate of elimination is the same as found in 
the intact rat and perfusion experiments, the heptyl derivative being 
eliminated most rapidly in all cases. 
R R 
Secobarbital, Pernocton and Rectidon were the only members of the 
allyl and bromo-allyl series which were metabolized in the hepatocyte 
suspensions. Noctal , brallobarbital and methylbrallobarbital were not 
eliminated or at a very slow rate. As in the intact liver experiments the 
bromo-allyl derivative is eliminated more rapidly than its allyl homologue. 
With the exception of heptabarbital the non-methylated derivatives of 
the ring-substituted barbiturates show also a low disappearance rate. 
N-methylation increases the rate of metabolism for all drugs studied. 
These N-methylated derivatives are metabolized very rapidly as is shown 
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Fig. 14.1 Elimination by isolated hepatocytes (2 χ 10 /ml) 
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Concentration at zero-time IS mg/l 
in Fig. 14.2. They are metabolized in the same fashion as their parent 
compounds and not or hardly not by demethylation. Methylheptabarbital is 
eliminated most rapidly, while methylreposal is metabolized a little 
slower. This is in agreement with the results of the liver perfusion. 
The half-lives and clearance constants of the derivatives studies 
are presented in Table 14.1, together with the values relative to hepta-
barbital. The importance of the standardization becomes apparent, when 
we compare the errors in the absolute and relative values. 
For most derivatives the half-life ratios and the clearance ratios, 
measured in the hepatocyte and perfusion experiments, are in the same 
order of magnitude. An exception is methylheptabarbital. Apparently, the 
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TABLE 14.1 
H a l f - l i v e s and clearances of some bar­
b i t u r a t e s in the hepatocyte suspension 
Compound 
Butyl 
Pentyl 
Hexyl 
Heptyl 
Seco 
Pern 
Rect 
m-Cyclo 
m-Hepta 
m-Rep 
Hepta 
Half-life 
(min) 
147.7+71.8 
50.5+31.3 
22.9+24.0 
11.2+ 6.6 
42.7+13.3 
26.3+11.0 
10.2+ 4.2 
5.9+ 0.7 
2.2+ 0.7 
3.4+ 0.6 
13.5+12.4 
( 3) 
( 6) 
( 7) 
( 4) 
( 3) 
( 3) 
( 3) 
( 4) 
( 4) 
( 4) 
(28) 
Half-life 
ratio 
19.8+5.7a 
4.8+0.9a 
1.4+0.Ia 
0.8+0.2a 
3.7+0.5a 
2.2+0.4b 
0.9+0.Ia 
0.7+0.Ia 
0.3+0.ib 
0.4+0.Ia 
Clearance 
(ml/min) 
0.14+0.09 
0.53+0.39 
1.58+0.06 
2.46+2.23 
0.52+0.11 
0.80+0.23 
2.13+0.60 
3.52+0.34 
10.40+2.66 
6.20+1.32 
2.17+1.48 
Clearance 
ratio 
0.06+0.02a 
0.22+0.04a 
0.73+0.06a 
1.27+0.22a 
0.28+0.03a 
0.43+0.04b 
1.12+0.11a 
1.52+0.15a 
4.38+0.77° 
2.64+0.49a 
1) ratio half-life and elearance (deTivative/heptabarbital) 
2) mean +_ S.D.; number of experiments in parentheses 
a. not significantly different from perfusion Ρ > 0.05 
b. signifioantly different from perfusion 0.001 < Ρ < 0.05 
a. signifioantly different from perfusion Ρ < 0.001 
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DISCUSSION 
The clearance of barbiturates in a suspension of about 6.10 hepatocytes 
increases strongly with increasing chain length from butyl to heptyl. 
Between different batches of hepatocytes there is quite some variation 
because of variation in the amount and the quality of the liver cells. 
For this reason and in order to allow a comparison with the liver perfu-
sion data, heptabarbital is used as a reference compound and clearance 
ratios have been given in Table 14.1. The clearance is linearly propor-
tional with the number of hepatocytes in the cell suspension (see chapter 
7). The intact rat liver contains about 120.10 hepatocytes (Zahlten, 
1974), that is about 20 times more than in the suspensions used in our 
experiments. The clearance of the barbiturates in the perfused liver is 
only 7-10 times larger than in the cell suspension. This may indicate 
that the isolated hepatocytes have a higher metabolic capacity than the 
isolated liver. It is possible that in the intact liver the real number 
of cells, engaged with the conversion of the barbiturates, is much lower 
than calculated. This may be caused by the internal structure of the 
liver and the arrangement of the cells within the organ. 
For compounds which are cleared very rapidly transport processes 
across the cell membrane may be rate limiting in the turnover of the 
compound. Accordingly, the clearance ratio for such compounds in the cell 
suspensions will be higher than that in the perfused liver experiments, 
since, as compared with the intact liver, in the hepatocyte suspension a 
larger surface is available for transport across the cell membrance. 
There are indications that this is the case with methylheptabarbital (see 
also chapter 15). 
The metabolites formed in the hepatocyte suspension appeared to be 
identical to those found in the intact liver experiments, indicating that 
the metabolic pathways in both systems are the same. 
Our findings indicate that hepatocytes as experimental material for 
metabolic studies are quite comparable with perfusion studies. 
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CHAPTER 15 
PHARMACOKINETICS OF BARBITURATES IN A SUBCELLULAR SYSTEM OF RAT LIVER 
INTRODUCTION 
During the last ten years many studies on the metabolic conversion of 
barbiturates by rat liver homogenates have been published. Most of these 
studies deal with enzyme kinetics in liver microsomes (McCarthy, 1970; 
Sitar, 1973), others deal with the nature of the metabolites formed 
(Holtzman, 1975; Kupfer, 1973). 
In spite of the numerous investigations on the metabolism of bar-
biturates in the intact rat and in liver microsomes, there are only a few 
comparative studies on drug metabolizing enzyme systems in liver homo-
genates and systems with intact cellular structure. However, a comparison 
is necessary in order to determine the reliability of data, obtained in 
subcellular systems with respect to systems with intact cells. 
The kinetics of barbiturate metabolism has been studied in a subcel-
lular system of rat liver (9000 g supernatant fraction) while a compari-
son is made between the kinetic data of the same substances in intact 
liver cells and the liver perfusions. 
METHODS 
Twenty per cent, (w/v) 9000 g homogenates in Tris (0.05 M) - KCl (0.15 M) 
buffer pH 7.4 were prepared according to the method of Kato (1967). The 
incubation mixture contained 5 ml of the supernatant fraction (equivalent 
to 1 gr of liver), 5 ml barbiturate solution (10 mg/100 ml Tris), 5 ml of 
a NADPH-regenerating system and 15 ml Tris pH 7.4. At various time inter-
vals samples of 0.5 ml were taken and transferred to tubes containing 
7 ml ether and internal stöndard (see also chapter 6). 
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RESULTS 
The elimination of the barbiturates from the incubation medium containing 
rat liver microsomes follows first order kinetics as may be seen from the 
semilogarithmic concentration-time curves, which aro straight lines. The 
curves for the 5-ethyl-5-alkyl substituted barbiturates are given in Fig. 
15.1. With increasing chain length of the substituent the rate of meta­
bolism increases as in the liver cells and in the intact liver. There is 
a good correlation between the sequence in disappearance rate in this 
subcellular system and the intact liver cell system (see chapter 14). 
The butyl derivative was metabolized so slowly that in the time course of 
the experiment no metabolism could be observed. The same holds for Talbu-
R R Ό 
tal , Noctal , brallobarbital and the N-methylated derivatives Eunarcon 
and methylbrallobarbital. 
r 
60 70 
Time (mm) 
Fig. 15.1 Elimination by 9000 g Tat liver supernatant 
• heptabarbital · heptyl derivative 
o hexyl derivative • pentyl derivative 
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In Figure 15.2 the curves of three bromoallyl substituted deriva-
R 
tives are presented. The curve of Noctal is very flat and is therefore 
R 
eliminated very slowly while Rectidon is eliminated very rapidly and 
about twice as rapidly as the reference compound, heptabarbital. This is 
in contrast with the results of the perfusion and cell experiments, where 
both drugs are eliminated at equal rate. 
20.0 
80 Time (min) 
F i g . 15.2 Elimination by 9000 g rat liver supernatant of some 5-bromo-
allyl-5-alkyl substituted barbiturates „ 
• heptabarbital · Rectidon 
Δ Pemooton· R D Nootal
R 
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The absolute and r e l a t i v e h a l f - l i v e s and c learance cons tant s of the 
der iva t ives s tudied are presented in Table 15.1. In c o n t r a s t with the 
r e s u l t s of the hepatocyte suspension, t h e data presented in Table 15.1 
suggest t h a t for most compounds there i s a considerable di f ference in 
clearance between t h e l i v e r perfusion and 9000 g supernatant experiments. 
TABLE 15.1 
Hal f- l ives and clearances of some b a r b i ­
t u r a t e s in the 9000 g supernatant suspension 
Compound 
Pentyl 
Hexyl 
Heptyl 
Octyl 
Nonyl 
Seco 
Pern 
Rect 
m-Cyclop 
Hexo 
m-Cyclo 
m-Hepta 
M-Rep 
Hep ta 
Half-li] 
(min) 
61.7+13.3 
12.5+ 3.1 
8.8+ 5.9 
8.3+ 4.5 
10.3+ 6.1 
55.2+ 5.1 
27.2+ 8.1 
4.8+ 1.4 
32.3+12.1 
17.4+ 4.6 
6.0+ 1.7 
1.6+ 0.5 
2.1+ 0.7 
10.3+ 4.4 
fe 
( 4) 
( 4) 
( 6) 
( 6) 
( 5) 
( 4) 
( 5) 
( 5) 
( 4) 
( 7) 
( 8) 
( 7) 
( 4) 
(27) 
Half-life 
ratio 
8.7+1.9b 
1.5+0.4a 
0.8+0.2b 
0.9+0.2b 
l.l+0.4a 
6.3+1.2b 
2.8+0.3b 
0.5+0.1° 
2.2+0.2b 
1.4+0.3a 
0.5+0. lb 
0.1+0.1° 
0.2+0. lb 
Clearance 
(ml/min) 
0.34+0.10 
1.68+0.44 
3.05+1.52 
3.10+1.43 
2.68+1.26 
0.37+0.03 
0.77+0.27 
4.42+1.65 
0.70+0.21 
1.27+0.28 
3.93+1.21 
14.78+3.95 
11.39+3.48 
2.26+0.82 
Clearance 
ratio 
0.12+0.03b 
0.70+0.12a 
1.26+0.2lb 
1.16+0.23b 
1.07+0.34b 
0.17+0.03b 
0.36+0.04a 
2.03+0.14° 
0.51+0.08b 
0.79+0.IIa 
2.31+0.40b 
8.11+1.39° 
5.38+1.05b 
1) ratio half-life and clearance (derivative/heptabavbital) measured in 
the same experiment 
2) mean + S. D. ; number» of experiments in parenthesis 
a. not significantly different from perfusion Ρ > 0.05 
b. significantly different from perfusion 0.00K P < 0.05 
a. significantly different from perfusion P < 0.001 
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As a result these barbiturates can be separated into two groups: the 
derivatives of which the clearance ratio perfusion/9000 g has become 
higher and the derivatives of which this ratio has become lower than 
unity (Table 15.2). 
TABLE 15.2 
Heptabarbital clearance ratios of hepatocyte and 9000 g experiments 
versus the heptabarbital clearance ratio measured in the perfusions 
Compound 
k„ , ratio cells k„ , ratio 9000 g 
Cel Cel ° 
k 0 . ratio perf. k„ , ratio perf. 
Cel r Cel r 
Butyl 0.82+0.26 _ 
Pentyl 0.75+0.19 0.42+0.11° 
Hexyl 0.90+0.08 0.87+0. 15a 
Heptyl 1.25+0.27 0.98+0. 13a 
Octyl 1.04+0.33 
Nonyl 0.66+0.35 
Seco 0.93+0.22 0.54+0.I6b 
Pern 1.37+0.17 1.14+0. 16a 
Reet 1.16+0.24 2.13+0.41e 
ш-Cyclop 0.62+0.11 
Нехо 0.63+0.09 
m-Cyclo 0.98+0.16 1.49+0.ЭЭЬ 
m-Hepta 1.72+0.36 3.13+0.68° 
m-Rep 1.09+0.27 2.22+0.59b 
α. not significantly different Ρ > 0.05 
b. significantly different 0.001 < Ρ < 0.05 
c. significantly different Ρ < 0.001 
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DISCUSSION 
One of the most striking differences between the 9000 g rat liver super­
natant and the preparations with intact liver cells is the metabolic 
pathway of the barbiturates. In the former the major metabolic end pro­
ducts are the hydroxy-metabolites, while in the lateer these metabolites 
are oxidized further (see chapter 18). This implies that in the 9000 g 
experiments there is an accumulation of hydroxy-metabolites, that may 
inhibit the metabolism of their precursors. This product inhibition may 
be due to an interaction with cytochrome Ρ 450 (Von Bahr, 1971; Stav-
chansky, 1974). In contradiction with this is the fact that the clearance 
of hexobarbital in the liver perfusion is not affected by the administra­
tion of a high dose of its hydroxy-metabolite to the perfusion medium. 
This metabolite penetrates into the liver cells because it is further 
metabolized to a keto derivative. Product inhibition may, however, occur 
with other members of the series. 
Noctal , brallobarbital and methylbrallobarbital are not measurable 
metabolized in the 9000 g supernatant suspension. This supports our 
earlier findings that these barbiturates are eliminated at a slower rate 
as conciar ed with the intact rat experiment, when presented directly to 
R 
the liver enzymes (see also chapter II and 24). Rectidon and methyl-
heptabarbital are very rapidly eliminated by 9000 g rat liver supernatant 
and intact liver cells but in the 9000 g rat liver supernatant even more 
rapidly than in the hepatocyte suspension when compared with the refer­
ence drug heptabarbital. This indicates that the capacity of the hepatic 
microsomal enzymes is higher than the supply of drug and may imply that 
for compounds which are rapidly eliminated transport across the liver 
cell membrane may become a limiting factor. Further evidence for the 
existence of a transport barrier in isolated hepatocytes is provided by 
a recent report (Von Bahr, 1974). It was shown that the hexobarbital 
uptake into hepatocytes occurs by a non-energy requiring process, which 
is dependent on the lipid solubility of the compound. Further it was 
shown that the rate of formation of the type I spectral change (see 
chapter 16) was lower for cells than for liver homogenates or microsomes. 
Results from 9000 g rat liver supernatant or liver microsomes may 
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not be extrapolated directly to гп vivo situation. The morphological 
features of the liver cells, the organization of the liver and the cir­
culatory aspects have to be taken into consideration. 
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CHAPTER 16 
THE DISSOCIATION CONSTANTS (K ) OF THE BINDING OF BAR­
BITURATES TO CYTOCHROME Ρ 450 OF RAT LIVER AND THE 
MICHAELIS-MENTEN CONSTANTS (K ) OF A NUMBER OF BARBITURATES 
ш 
INTRODUCTION 
For many drugs there seems to exist a relationship between the ability 
to produce a spectral change with liver microsomes and to undergo oxi­
dative metabolic conversion (Schenkman, 1967). This suggests that drug 
binding to the microsomes is an obligatory step in the mechanism of drug 
oxidation. The dissociation constant, obtained by spectral difference 
measurement, is regarded as a measure of the affinity of the substrate 
for cytochrome Ρ 450. 
Although various studies have been undertaken to measure the К 
values of certain barbiturates (Degwitz, 1969; Jansson, 1972; Topham, 
1970), systematic studies on large series of barbiturates are still 
lacking. We have, therefore, determined the К values of a large number 
of barbiturates and have correlated К values with the lipophilicity and 
the metabolic clearance of the compounds. 
RESULTS 
In the concentration ranges used all barbiturates showed a type I spec­
tral change with an absorption minimum at 420 nm and a peak at 390 nm. 
Figure 16.1 shows the spectral change of a number of 5-ethyl-5-alkyl 
substituted barbiturates, added to a final non-saturating concentration 
of 0.22 nMol. There is an increase in spectral change from the propyl to 
the heptyl derivative, while a further lengthening of the alkyl side 
chain results again in a smaller spectral change. In Table 16.1 the dis­
sociation constants of the 5-ethyl-5-alkyl series, based on the induced 
spectral change, are listed. Our values for the butyl and s-pentyl deri­
vative are consistent with those reported by Jansson (1971). The value of 
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the i-pentyl derivative is in agreement with that of Topham (1970) and 
Sitar (1973). 
• 0 02 ι 1 
Wavelength (nm) 
Fig. 16.1 Type I spectral change caused by ethyl-alkyl barbiturates 
final concentration 0.22 mMol 
Figure 16.2 shows the reciprocal plots of induced spectral changes 
of a number of 5-allyl-5-alkyl substituted barbiturates. As in the pre­
vious series there is clearly a relationship with the length of the 
alkyl substituent. Table 16.2 presents the values of the 5-allyl-5-alkyl 
and 5-bromoallyl-5-alkyl series together with some N-methylated homo­
logues. In both groups there is an increase in affinity for cytochrome 
Ρ 450 with increasing alkyl side chain. The К values of the bromoallyl 
substituted barbiturates are lower than those of their allyl substituted 
homologues. 
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TABLE 16.1 
К values of a number of 5-ethyl-
-5-alkyl s u b s t i t u t e d b a r b i t u r a t e s 
Compound 
Propyl 
Butyl 
P e n t y l 
i - P e n t y l 
s - P e n t y l 
2,3-But 
Hexyl 
Heptyl 
Octyl 
Nonyl 
K
s 
0 . 0 8 9 + 0 . 0 0 9 
0 . 0 8 9 + 0 . 0 0 9 
0 . 0 3 2 + 0 . 0 0 4 
0 . 0 3 8 + 0 . 0 1 7 
0 . 0 4 5 + 0 . 0 1 2 
0 . 0 2 5 + 0 . 0 0 2 
0 . 0 1 9 + 0 . 0 0 3 
0 . 0 2 0 + 0 . 0 0 4 
0 . 0 2 4 + 0 . 0 0 2 
0 .056+0.011 
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Fig . 16.2 Reciprocai plots of changes in dbsovbance at 420 nm relative 
to 390 nm caused by consecutive additions of S-allyl-5-alkyl 
substituted barbiturates to microsomal suspensions 
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TABLE 16.2 
К values of a number of 5-allyl-
s 
-5-alkyl and 5-bromoallyl-5-alkyl 
substituted barbiturates 
Compound К 
Allo 
Apro 
Tal 
Neal 
Seco 
Brallo 
No et 
Pem 
Re et 
ш-Bral 
Eunarc 
m-Pem 
0.394+0.064 
0.219+0.047 
0.098+0.008 
0.061+0.007 
0.028+0.002 
0.136+0.030 
0.105+0.015 
0.031+0.005 
0.013+0.001 
0.103+0.013 
0.034+0.001 
0.012+0.001 
Figure 16.3 shows the reciprocal plots of a number of N-methylated 
5-ethyl-5-cycloalkenyl substituted barbiturates. There is apparently an 
optimum in affinity for the cycloheptenyl substituted derivative. In 
Table 16.3 the К values are listed of a number of N-methylated barbi-
s 
turates with a cyclic substituent at the 5-position, together with their 
nor-homologues. As in the previous series the N-methylated derivatives 
have lower К values than their non-methylated homologues, they there­
fore bind stronger to the enzyme Ρ 450. Topham (1970) reports a К value 
for norhexobarbital and hexobarbital of 0.08 and 0.09 mMol respectively, 
while Jansson (1973) reports for hexobarbital a value of 0.08 nMol. This 
discrepancy with our values may be caused by the fact that these authors 
have determined the К values in microsomes of phenobarbital-induced 
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rats. Attempts have been made to correlate the К values of the various 
barbiturates with their partition coefficients (log P). 
TABLE 16.3 
К values of a number ring-sub­
stituted barbiturates and their 
N-methylated homologues 
Compound 
Norhexo 
Cyclop 
Cyclo 
Hep ta 
Rep 
Hexo 
m-Cyclop 
nr-Cyclo 
m-Pheno 
m-Hepta 
m-Rep 
0.099+0.003 
0.080+0.010 
0.041+0.003 
0.022+0.002 
0.026+0.004 
0.036+0.003 
0.025+0.001 
0.024+0.002 
0.023+0.003 
0.015+0.002 
0.017+0.001 
In Figure 16.4 a curve is shown, which presents the relationship 
between log Ρ and the affinity for cytochrome Ρ 450, according to a 
parabolic function. A good correlation was found (r 0.935, s 0.105; for 
log Ρ
 1 Ί г 0.967, s 0.121). This is consistent with the reports of 0
 cells ' 
Hansch (1968) on the parabolic dependence of pharmacological activity 
upon the lipophilic character of the compounds. In the 5-ethyl-5-alkyl 
series the lipophilicity was increased by increasing the chain length. 
Increased binding may not be caused by increased lipophilicity but by 
the conformation of the alkyl chain. Lipophilicity was, therefore, also 
increased by N-methylation while the conformation of the alkyl group 
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УДЕ 
040 
Fig. 16.3 Reciprocai •plots of changes in absorbance at 420 nm relative 
to 390 run caused by consecutive additions of N-methylated 
ring-substituted barbiturates to microsomal suspensions 
log (P-octanol) 
Fig. 16.4 S-ethyl-S-alkyl series. 
Relationship between log Ρ and the affinity to cytochrome 
Ρ 450 described by a parabolic function (r 0.9Z5, s 0.105) 
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remained unchanged. In Table 16.4 the К values of some N-methylated 5-
-ethyl-5-alkyl barbiturates are listed together with their octanol/water 
partition coefficients. The data presented in Table 16.4 indicate that 
the length of the substituent, rather than the lipophilicity per se is 
responsible for the descending part of the curve, presented in Figure 
16.4. 
TABLE 16.4 
К values and partition coefficients 
s
 r 
of some N-methylated 5-ethyl-5-alkyl 
substituted barbiturates 
Compound 
m-Hexyl 
m-Heptyl 
m-Octyl 
m-Nonyl 
K
s 
0.008+0.001 
0.009+0.002 
0.011+0.002 
0.020+0.003 
log TPC 
oct/water 
3.26 
4.16 
4.25 
4.34 
As mentioned previously apparent Michaelis-Menten constants can be 
obtained in liver systems by administration of saturating dosages. Fig. 
16.5 shows the concentration-time curve of 5-ethyl-5-octyl barbituric 
acid in the isolated perfused rat livet system. From this curve the 
Michaelis-Menten constant (K ) and the metabolic capacity (Q ) can be 
m ш 
calculated with the following equations (Van Ginneken, 1974): 
0.4343 A 
К = and 
m (log A" - log Α) Ίη 
In Table 16.5 some preliminary results are presented 
К k„ . 
m Cel 
117 
Fig. 16.5 Saturation aicrve of 5-ethyl-S-oatyl barbiturÌa acid (35 mg) in 
the ieolated perfused rat liver system 
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TABLE 16.5 
К and 0 values of some barbiturates measured 
m τη 
in the isolated perfused rat liver 
Compound 
Hep ta 
Octyl 
m-Cyclo 
Hexo 
Rect 
К 
m 
(πΜοΙ) 
0.26 
0.25 
0.29 
0.24 
0.36 
0.32 
0.30 
0.36 
0.31 
0.25 
0.21 
«m 
(uMol/min) 
2.56 
2.06 
9.261 
2.41 
2.23 
2.44 
2.49 
9.96' 
4.182 
3.88 
2.11 
1) phenobarbital-induoed 
2) oalaulated from Stitz&l (1968) 
DISCUSSION 
Our results suggest that there exists a relationship between the К 
values and the chemical structure of the barbiturates. The introduction 
of larger substituents either aliphatic or cyclic at the 5-position of 
the barbituric acid ring, results in a decrease in К . This is consis­
tent with the data of Topham (1970). The bromoallyl substituted and N-
-methylated barbiturates have lower К values than the corresponding 
s 
allyl substituted and non-methylated homologues. In the various homo­
logous series this corresponds very well with the metabolic clearance. 
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Generally, compounds with a low К value are metabolized faster than 
those with higher К values. However, a quantitative relationship cannot 
be found. 
Studying derivatives with no more than 6 or 7 carbon atoms in the 
side chain, as are used in clinical medicine, may lead to the conclusion 
that the 1С is only dependent on the lipophilicity of the compounds 
(Topham, 1970). Our results, however, indicate that with longer substi­
tuants the influence of a steric effect, opposite to the lipophilicity, 
becomes visible. This phenomena may be responsible for the flattening of 
the curve, representing the relationship between the clearance and the 
lipophilicity. The relationship between К values and metabolism is com­
plex. Besides an affinity for the metabolizing enzymes, the rate of me­
tabolism is dependent on the sensitivity of the substituent to metabolic 
attack, as appears from the К values and clearance ratios of nealbarbi-
tal and methylphenobarbital. 
The К values are about a factor 10 smaller than the corresponding 
К values measured from metabolic conversion. Furthermore the metabolic 
m 
clearance rate does not match the К or К values. This implies that 
e m 
binding to the metabolic enzymes is not the only factor responsible for 
the relationship between structure and pharmacokinetic properties. 
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SECTION IV 
METABOLISM OF BARBITURATES 
CHAPTER 17 
PHARMACOKINETICS OF BARBITURATE METABOLITES 
INTRODUCTION 
The barbiturates are eliminated from the body mainly by metabolic degra-
dation in the liver. Metabolism predominantly occurs by oxidation of the 
substituents at the 5-position of the barbiturate nucleus (Mark, 1969; 
Maynert, 1949). 
Especially, the metabolism of 5-(cyclohexenyl) substituted deriva-
tives, such as hexobarbital and cyclobarbital, has been studied inten-
sively (Bush, 1973¡ Tsukamoto, 1958). Hexobarbital is generally used as 
model substrate for microsomal hydroxylation. In several studies the К 
m 
value of this barbiturate has been determined, not only by following the 
disappearance of substrate, but also by measuring the formation of the 
hydroxy-metabolite (McCarthy, 1971; Sitar, 1971). 
Although hydroxylation of the side chain appears to be a general 
route of inactivation, little is known about the fate of such hydroxy-
-metabolites. These metabolites lack pharmacological activity, but they 
may exert toxic action or in the course of their formation toxic inter­
mediates may be formed. 
In support of our studies on the pharmacokinetics of barbiturates, 
we have also investigated the pharmacokinetics of some of their metabo­
lites. 
RESULTS 
In the isolated perfused rat liver hexobarbital is rapidly converted into 
a hydroxy-metabolite, which in turn is further metabolized into a corre­
sponding keto-derivative, see Figure 17.1. The hydroxy-metabolite is more 
slowly eliminated than the parent compound, while the keto-product is 
still more resistent to elimination. The latter compound is apparently 
a metabolic end product that in vivo is cleared by the kidney. In the 
intact rat keto-hexobarbital is the major metabolite excreted by the 
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Fig. 17.1 Time courses of hexobarbital and its metabolites in the iso­
lated perfused rat liver system 
kidney to about 57% of the dose (Holcomb, 1974). N-demethylation does 
not take place in the isolated rat liver nor in the intact rat. In fact 
the N.N'-dimethyl and the N-methyl derivatives are metabolized according 
to the same pattern as the non-methylated barbiturates (see scheme in 
Fig. 17.2). The rate of metabolic conversion of the Ν,Ν'-dimethyl, N-
-methyl and non-methylated derivatives, however, is different. The Ν,Ν'-
-dimethyl derivatives are more rapidly metabolized than their N-methyl 
homologues; the latter in turn more rapidly than the non-methylated 
compounds. 
In Figure 17.3 the time courses of NjN'-dimethylcyclobarbital and 
its metabolites in the perfusate are shown. As for the N-methyl deriva­
tives the hydroxy-metabolite is converted to the ketone. This ketone, 
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Fig. 17.2 Scheme of metabolites of 5-cycZohexenyl substituted barbitu­
rates 
however, disappears from the perfusate. Since in our analysis other me­
tabolites could not be determined, the metabolic fate of this ketone is 
unknovm. It may be converted to a malonuric acid derivative by cleavage 
of the barbiturate nucleus, as has been reported for hexobarbital (Bush, 
1973). 
In Table 17.1 the half-life ratios of the metabolites to their 
parent compounds are presented. The half-life ratios of the hydroxy-me-
tabolites of the two cyclohexenyl substituted derivatives are similar. 
5-Ethyl-5-alkyl substituted barbiturates have been reported to 
undergo side chain oxidation at the penultimate position to form an al­
cohol. For butobarbital, pentobarbital and amobarbital the 3-hydroxy-
-metabolites are reported to be the major urinary metabolites, together 
with the carboxy-metabolites (Maynert, 1952, 1965). 
Numerous studies on the formation and the stereo-chemistry of these 
alcohols have been published, but only a few data are available with 
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F i g . 17.3 Time courses of 1,3-NjN'-dimethylcyclobarbital and its meta­
bolites in the isolated perfused rat liver preparation. Since 
no reference compounds of the metabolites are available, the 
ratio of the metabolite peak areas to that of the internal 
standard have been plotted. 
regard to the keto-metabol i tes (Gi lber t , 1974; Kuntzman, 1967). In our 
G.C. analys i s of the experiments with 5-ethyl-5-alkyl s u b s t i t u t e d b a r b i ­
t u r a t e s only one "metaboli te"-peak could be detected. However, a f t e r 
methylation and subsequent s i l y l a t i o n of the samples, according t o the 
method of G i l b e r t (1974), t h i s peak resolved in our G.C. ana lys i s i n t o 
more peaks (see a l so chapter 19). 
In Figure 17.4 the time courses of N.N'-dimethyl-S-ethyl-S-hexyl 
b a r b i t u r i c acid and i t s metabolites are shown. Apparently, two alcohols 
are formed. This i s c o n s i s t e n t with the data of Maynert (1965), who r e ­
ported for 5-ethyl-5-hexyl b a r b i t u r i c acid the formation of two a lcohol ic 
odimeHrylcyclobarbital (25rng-1 
• hydroxy metabolite 
o keto-metabolite 
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TABLE 17.1 
Half-life ratio metabolite/parent compound 
of some barbiturates in the isolated per-
fused rat liver system 
Compound 
Hexo 
m-Cyclo 
DnrCyclo 
m-Hepta 
ra-Rep 
Half-life 
À 
2.68+0.31 
2.75+0.28 
1.81+0.05 
4.75+1.42 
6.71+0.91 
(5) 
(5) 
(3) 
(3) 
(3) 
ratio 
В 
4.46+0.80 (3) 
A. half-life ratio hydroxy-metabolite/parent oompovnd 
B. half-life ratio keto-metabolite/parent compound 
Number of experiments in parentheses 
metabolites. The 5-hydroxy derivative is the major alcoholic metabolite. 
Both alcohols are oxidized further to their keto-homologues, as appears 
from our G.C. and G.C. combined mass spectrometry analysis. The 4-hy-
droxy compound is oxidized more rapidly than the 5-hydroxy-metabolite. 
The bromoallyl substituted barbiturates have been shown to be con­
verted to the hydroxy-propyl and acetonyl metabolites (Ravn-Jonsen, 
1970; Keding, 1969). For methylbrallobarbital the acetonyl-metabolite 
was found to be the principal metabolite. Figure 17.5 shows the time 
courses of this barbiturate and its metabolite in the isolated perfused 
rat liver system. 
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Fig. 17.4 Metabolism of l^S-NjN'-d'imethyl-S-ethi/l-S-hexyl barbituric 
acid by the isolated perfused rat liver 
D li3-NJN
,
-dimethyl-S-ethyl-S-hexyl barbituric acid 
χ 4-hydroxy-metabolite 
• 5-hydroxy-metabolite 
O keto-metabolite(s) 
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Fig. 17.5 Metabolism of l-N-methylbrallobarbital by the isolated per­
fused rat liver 
• 1-N-methylbrallobarbital 
О acetonyl-metabolite 
DISCUSSION 
As appears from our results, the isolated perfused rat liver system is 
an excellent tool to study the pharmacokinetics of the metabolites of 
barbiturates. In this system many samples can be taken, which is neces­
sary to follow the time courses of the metabolites accurately. 
Various studies have been reported on the metabolism of hexobarbi-
tal by the isolated perfused rat liver (Bock, 1974; Holcomb, 1974; 
Stitzel, 1968). However, information about the pharmacokinetics of the 
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metabolites has not been given. This paper is the first, as far as known, 
which presents some information about the pharmacokinetic behaviour of 
barbiturate metabolites. It is shown that the metabolites formed by oxi-
dation in the 5-substituent are more slowly eliminated than their cor-
responding parent compound. The keto-metabolites are more resistent to 
further metabolism than the hydroxy-metabolites. Knowledge of the half-
-lives of the metabolites is necessary with respect to a possible in-
hibitory action of these metabolites on the metabolism of other drugs, 
present in the body. Recently, it was shown in vitro that hydroxylated 
metabolites of one drug can inhibit the biotransformation of another 
drug (Stavchansky, 1974). 
In view of the difference in lipophilicity between hexobarbital and 
its hydroxy-metabolite (Bush, 1973) the half-life ratio presented in 
Table 17.1 is rather surprising. A similar value has been reported in 
man for the half-life of amobarbital and its metabolite (Draffan, 1973). 
Table 17.1 shows further, that for the derivatives with larger sub-
stituents, the difference between the parent compounds and their alco-
holic metabolites becomes larger. Our results may indicate that either 
the barbiturates and their hydroxy-metabolites interact differently with 
the metabolizing enzyme system or with different enzymes (enzyme sites). 
The latter view is consistent with the observation that a soluble enzyme 
in the 9000 g fraction of liver homogenates is required for the forma-
tion of keto-hexobarbital (Toki, 1964) and keto-pentobarbital (Kuntzman, 
1967). 
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CHAPTER 18 
METABOLIC DIFFERENCES BETWEEN THE ISOLATED HEPATOCYTE 
SUSPENSION AND THE 9000 G RAT LIVER SUPERNATANT 
INTRODUCTION 
With the 9000 g fraction of liver homogenates one can do many parallel 
experiments with aliquote of material from one liver. However, one of 
the major drawbacks of this preparation is the destruction of the cellu-
lar integrity, which obviously has consequences for the metabolism in 
this preparation. 
Many studies have demonstrated differences in the metabolism of 
barbiturates between experiments with whole animals or perfused organs 
and the 9000 g fraction of liver homogenates (Kuntzman, 1967; Sitar, 
1973). Hydroxy-metabolites of barbiturates have been reported to be con-
verted by enzymes, presented in the soluble fraction of the liver. Toki 
(1964) demonstrated the existence of several alcohol dehydrogenases for 
the conversion of hydroxylated barbiturates. 
The development of techniques to isolate viable hepatocytes suc-
cessfully made it possible to carry out parallel experiments with the 
preservation of the cellular structure. We have compared the metabolic 
performance of these two in vitro systems and have done some inhibition 
studies with ethanol in order to investigate the enzyme systems which 
are involved in the formation of the hydroxy- and keto-metabolites of 
barbiturates. 
RESULTS 
Figure 18.1 shows the time courses of N-methylcyclobarbital and its me-
tabolites in a hepatocyte suspension. As in the perfusion experiments 
the barbiturate is converted to the hydroxy-metabolite, which in turn is 
oxidized rapidly to its keto-homologue. The keto-metabolite is apparent-
ly the metabolic end product. 
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Fig. 18.1 Metabolism of l-N-methylcyclobarb-ital by isolated rat hepato-
cytes (2 χ 10b/ml) 
• l-N-methylsyalobarbital (0.5 mg) 
x hydroxy-metabolite 
О keto^metaholite 
Figure 18.2 presents the time course of the same barbiturate and 
i t s metabolite in the 9000 g rat liver supernatant. In this preparation 
the alcohol is the only metabolite, which can be demonstrated in our 
G.C. analysis. In contrast with the hepatocyte suspension, the alcohol 
is apparently not further oxidized. 
Addition of ethanol to a hepatocyte suspension has no effect on the 
disappearance rate of the parent barbiturate and the formation of the 
hydroxy-metabolite, as is shown in Figure 18.3. The further oxidation of 
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Fig. 18.2 Metabolism of l-N-metkylcyclobarb-ital by 9000 g rat liver 
eupematant 
• l-N-methylayolobarbital (0.4 mg) 
x hydroxy-me tabolite 
the alcohol to the keto-metabolite, however, is inhibited considerably. 
This results in higher levels of the hydroxy-metabolite, as compared 
with the control. Our results are in agreement with the data of Cinti 
(1973), who found that pentobarbital hydroxylation by the microsomal 
fraction was not affected by ethanol concentrations in the range of 
2-50 mMol. 
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Fig. 18.3 Effect of ethanol on the metabolism of N-methylayolobarbital 
by isolated rat hepatooytes (3 χ 10 /ml) 
0 N-methylayolobarbital (0.13 mM) 
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DISCUSSION 
Our results indicate that, contrary to the 9000 g rat liver supernatant, 
the isolated rat hepatocyte suspension as metabolizing system is quite 
comparable with the isolated perfused liver. Not only with respect to 
the elimination rate of the barbiturates themselves (see chapter 14), 
but also with respect to the formation of their metabolites. 
Interesting is the selectivity of the inhibitory effect of ethanol 
on the metabolism of the hydroxy-metabolite. Haininen (1972) reports 
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that addition of ethanol to liver perfusions does not cause any redox 
changes in cytochrome Ρ 450, while according to Cinti (1973) ethanol 
does not bind to cytochrome Ρ 450. This may be an explanation, why the 
elimination of the parent compound is not inhibited. 
Several authors have found a NAD dependent oxidation of alcohols to 
ketones by the soluble fraction in the liver. It may be that ethanol 
competites with the hydroxy-metabolite for the same co-factors. We have 
found that in damaged hepatocytes (Trypan Blue exclusion less than 50%) 
the elimination of the hydroxy-metabolite is much more retarded than 
that of the parent compound (Fig. 18.4). It may be that there is a 
leakage of some essential factors to the extracellular space. However, 
more experiments are necessary to establish the nature involved in the 
degradation of hydroxy-metabolites of barbiturates. 
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Fig. 18.4 Influenae of oellular damage ση the metabolism of (+) and (-) 
hexobarbital 
О hexobarbital 
χ hydroxy-metabolite 
a keto~metabolite 
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CHAPTER 19 
IDENTIFICATION OF BARBITURATES AND THEIR METABOLITES 
INTRODUCTION 
G.C. combined mass spectrometry allows the identification of components 
of a mixture, which are present in low quantities by comparison with the 
mass spectra of known compounds. The mass spectra of barbiturates reflect 
the high stability of the barbiturate nucleus towards fragmentation. The 
5,5-di-substituted barbiturates show preferentially radical cleavage or 
McLafferty rearrangement processes of the side chains at the 5-position, 
as appears from the numerous reports in the literature (Arnold, 1969; 
Coutts, 1968; Grützmacher, 1966). 
The mass spectra of the 5-ethyl-5alkyl and 5-allyl-5-alkyl substitut-
ed barbiturates are characterized by the presence of abundant ions at 
m/e 141; 156 and m/e 167; 168 respectively, due to loss of the larger 
alkyl substituent. Distinction between the derivatives within each series 
is based on ions of low abundance and is often difficult. However, the 
presence of the two characteristic ions is helpful in the recognition of 
the "barbiturate" character of compounds as well as in synthesis of bar-
biturates as in metabolic studies. The 5-alkyl-5-cycloalken-l-yl sub-
stituted derivatives can be identified more easily, since they lose pre-
ferentially the short alkyl side chain (Gilbert, 1970). This results in 
abundant ions, the mass of which depends on the cyclic substituent. 
Barbiturates are reported to be metabolized mainly to hydroxy- and keto-
-metabolites. Identification of these metabolites can be facilitated by 
conversion to derivatives, p.e. hydroxyl groups may react with silylating 
reagents, which often results in a shift in G.C. retention time; 
N-methylation of the barbiturates usually gives greatly improved results 
with respect to the G.C. analysis. 
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EXPERIMENTAL 
Mass speetrometria aonditiona 
Mass spectra were obtained with a L.K.B. 9000 gas chromatograph-mass 
spectrometer. The apparatus was equipped with a glass column (1.8 m, 
3 mm I.D.), packed with 3% OV-17 on gas-chrom Q 60-80 mesh. Helium was 
used as carrier gas at a flow rate of 10-20 ml/min. Temperature: oven 
200-240OC; separator 260oC; ion source 170OC. Electron energy 20-70 EV, 
accelerating voltage 3.5 kV, trap current 60 μΑ, U.V. recorder paper 
Kodak, type 1895, spec. III. 
Methylation and silylation 
Methylation with diazomethane and silylation with bis-trimethylsilyltri-
fluor acetamide (BSTFÂ) was performed according to Gilbert (1974). 
RESULTS 
The metabolites of non-methylated and N-methylated derivatives have 
after conversion to the dimethylated derivatives with diazomethane the 
same G.C. retention times and mass spectra as the metabolites of the di-
methylated barbiturates. This indicates that N.N'-dimethyl, N-methyl and 
non-methylated barbiturates are metabolized similarly, while they only 
differ in the velocity of metabolism. Therefore, the N.N'-dimethylated 
barbiturates are excellent tools to study the metabolism of barbiturates, 
since they are converted most rapidly. 
Cyaloalkenyl subetituted barbiturates 
In Figure 19.1 the gas chromatogram of a sample of an incubation with 
methylhexobarbital is shown. The treatment with BSTFA results in the 
formation of two other peaks before the original position of peak 1. In 
Figure 19.2 the mass spectrum and fragmentation scheme, analogous to 
Arnold (1969) of peak la is shown. Comparison with the mass spectrometric 
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Fig. 19.1 Gas ehrowatograrrts of a aarnple of a perfusion experiment with 
methylhexobarbital before (lower) and after (upper) silylation 
data of 3-hydroxy-hexobarbital (Gerber, 1971) and 3-hydroxy-heptabarbi-
tal (Gilbert, 1974) suggests that this compound is identical with the 
3-hydroxy-me taboli te. 
The identity of peak lb is still unknown. Peak 2 does not show a 
shift in G.C. retention time on silylation. The mass spectrum and frag­
mentation scheme, analogous to that presented for 3-keto-hexobarbital 
(Arnold, 1969) is shown in Figure 19.3. The ion at m/e 95 points to the 
presence of a cyclohexenone group (Arnold, 1969). The mass spectrum of 
peak 2 is identical with that of methylated 3-keto-hexobarbital (Breimer, 
1974). 
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Fig. 19.2 Fvagmentation scheme of silylated hydroxy-methylhexobarbital 
and the mass spectrum of peak la 
S-Ethyl-S-alkyl substituted barbiturates 
In contrast with the cycloalkenyl substituted barbiturates in our G.C. 
analysis of experiments with 5-ethyl-5-alkyl barbiturates and their me­
thylated homologues there is always only one "metabolite"-peak present. 
In Figure 19.4 two gas chromatograms of experiments with the N.N'-di-
methylated hexyl derivative are shown, after silylation. Before silyla-
tion there was only a rather broad peak at the position of peak 5. The 
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Fig. 19.3 Fragmentation scheme of keto-methylhexobarbital and the mass 
spectrum of peak 2 
shift of peak 3 and peak 4 on silylation suggests the presence of 
hydroxy1 groups in these compounds. Peak 5 is not present in the 9000 g 
sample. 
There are indications that these peaks represent some hydroxy- and 
keto-metabolites (see also chapter 17, Fig. 17.4). However, the final 
proofs of their structures await the synthesis of the reference com­
pounds . 
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Fig. 19.4 Gas ahromatograms of silylated samples of l,3-N,N'-dtmethyl-
-5-ethyl-5-hexyl barbituric aaid in the 9000 g rat liver 
supernatant inoubation (left) and liver perfusion (right) 
S-Bromoallyl-5-alkyl substituted barbiturates 
In our G.C. analysis of experiments with N-methylbrallobarbital a "meta-
bolite"-peak always appears with a shorter retention time than the 
parent compound. Figure 19.5 shows the mass spectrum and fragmentation 
R 
scheme, analogous to that described for a metabolite of Noctal , 5-
-bromoallyl-5-isopropyl barbituric acid (Arnold, 1969). 
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Fig . 19.5 Fragmentation scheme of a metabolite of N-methylbrallobarbital 
in the isolated perfused rat liver 
DISCUSSION 
The formation of 3-hydroxy- and 3-keto-methylhexobarbital as principal 
metabolites of methylhexobarbital is in agreement with the numerous 
reports on the metabolism of hexobarbital (Gerber, 1971; Holcomb, 1974). 
The shift and the resolution in two other peaks on silylation of peak 1 
in Figure 19.1 suggest the presence of two alcoholic metabolites. This 
would be in agreement with the report on the metabolism of heptabarbital 
(Gilbert, 1974). This author describes the presence of two alcoholic 
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metabolites. The compound with the shortest G.C. retention time is 
identical with the 3-hydroxy-metabolite, while the other compound with 
a longer G.C. retention time is supposed to be the 7-hydroxy-homologue. 
The presence of probably two hydroxy-metabolites in the experiments 
with the Ν,Ν'-dimethylated hexyl derivative (Fig. 20.1) is consistent 
with the findings of Maynert (1965). 
Hydroxylation, resulting in the formation of several alcoholic me­
tabolites, has been reported too for l-N-butyl-5f5-diethyl barbituric 
acid (Vore, 1974). Moreover, it was shown that N-dealkylation of barbi­
turates in rats is negligible. 
The mass spectrum of the metabolite of 1-N-methylbrallobarbital 
R 
corresponds with that of the Noctal metabolite and this suggests that 
this compound is identical with the acetonyl-metabolite of methylbrallo-
barbital in dogs, in which as principal urinary metabolite the acetonyl 
compound was demonstrated (Keding, 1969). Different findings have been 
observed for the urinary metabolites of Eunarcon (l-N-methyl-5-bromo-
allyl-5-isopropyl barbituric acid) in rats. As principal metabolite was 
found l-N-methyl-5-(2'-oxo-3l-hydroxypropyl)-5-isopropyl barbituric acid 
(Ravn-Jonsen, 1970, 1973). 
It is important to elucidate the metabolic fate of the bromoallyl 
substituent, since bromoallyl substituted barbiturates have been report­
ed to possess toxic properties (Hoick, 1936; Yih, 1976). 
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SECTION V 
INTRAVENOUS AND ORAL ADMINISTRATION OF BARBITURATES 
CHAPTER 20 
PHARMACOKINETICS OF BUTOBARBITAL AND CYCLOBARBITAL 
FOLLOWING INTRAVENOUS AND ORAL ADMINISTRATION 
INTRODUCTION 
In clinical medicine, barbiturates are generally administered orally. 
This implies that the drug is involved in many processes, before it 
reaches the general circulation, such as absorption from the stomach and 
the passing through the liver by the portal system. These processes may 
result in changes in metabolic elimination (Barber, 1974). Therefore, we 
have studied the pharmacokinetics of two commonly used barbiturates, 
butobarbital and cyclobarbital, following intravenous and oral admini-
stration. 
RESULTS 
In Figure 20.1 the blood concentration-time curves of butobarbital are 
presented following intravenous and oral administration in the same rat. 
The half-lives of the two curves are similar. The bioavailability of the 
oral administration, determined by comparison with the intravenous curve, 
is about 1. This could be expected considering the ratio of the hepatic 
clearance and the liver blood flow (Rowland, 1972). 
Figure 20.2 shows the curves of cyclobarbital after intravenous and 
oral administration in the same rat. The absorption rate of cyclobarbi-
tal in rats is very high, so that often a part of the distribution phase 
becomes visible. The half-lives of the elimination phase of the two 
curves do not differ significantly. The bioavailability of cyclobarbital 
after oral administration is low, as appears from the difference in the 
levels of both curves. 
For butobarbital we have determined the blood concentration and 
some tissue levels at the moment of the loss and the regain of the 
righting reflex. The results are presented in Table 20.1. Intravenous 
injection of butobarbital in rats results in the loss of the righting 
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Fig. 20.1 Blood ooncentration-time аілг еа of butobarbital following 
intravenous and oral administration in the same rat 
Horizontal bars: sleeping times (min) 
reflex within 2 min. At that moment the equilibrium between the blood 
and the brain is clearly not reached, as is the case for the liver and 
the kidneys. The blood-brain ratio at the loss of the righting reflex 
and the values at awakening of both routes of administration become 
unity. In contrast with the brain, the liver and the kidneys equilibrate 
very rapidly with the blood and can be considered to belong to the cen­
tral compartment. The differences in blood and brain concentration at 
the loss and the regain of the righting reflex in the oral administra­
tion are not significant. There are no indications for the development 
of acute tolerance, as has been reported for other barbiturates (Aston, 
1965; Turnbull, 1976). 
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Fig . 20.2 Blood oonoentration-time curves of cyelobarbital following 
intravenous and oral administration in the same rat 
Horizontal bars: sleeping times (min) 
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TABLE 20.I 
Butobarbital concentrations in blood (mg/l) and tissues (mg/kg) at the 
moment of the loss (upper) and the regain (lower) of the righting reflex 
Dose 
15 
15 
15 
25 
25 
25 
15 
15 
15 
25 
25 
(mg) 
i.V. 
i.V. 
i.v. 
p.o. 
p.o. 
p.o. 
i.V. 
i.V. 
i.V. 
p.o. 
p.o. 
Blood 
164 
230 
173 
55 
86 
55 
53 
53 
37 
57 
43 
Brain1 
48 
65 
43 
54 
70 
66 
48 
59 
41 
58 
47 
(0.29) 
(0.28) 
(0.25) 
(0.98) 
(0.81) 
(1.20) 
(0.91) 
(1.11) 
(1.10) 
(1.02) 
(1.09) 
Liver1 
289 
371 
288 
117 
157 
129 
95 
103 
82 
95 
115 
(1.76) 
(1.61) 
(1.66) 
(2.13) 
(1.83) 
(2.34) 
(1.70) 
(1.94) 
(2.21) 
(1.67) 
(2.67) 
Kidneys' 
201 
192 
233 
98 
107 
806 
54 
75 
59 
101 
122 
(1.23) 
(0.83) 
(1.75) 
(1.78) 
(1.24) 
(1.45) 
(1.02) 
(1.41) 
(1.59) 
(1.77) 
(2.84) 
1) tissue/blood ratio in parentheses 
DISCUSSION 
Our results indicate that for the studied derivatives the half-lives are 
not affected by the route of administration. Similar results were ob-
tained in man with pentobarbital (Smith, 1973) and hexobarbital (Breimer, 
1974). 
Cyclobarbital, administered orally, has a low bioavailability, com-
pared with the intravenous route. The bioavailability of cyclobarbital, 
administered orally in man, is about 0.95, calculated after Breimer 
(1974). Since in rats the ratio hepatic clearance/liver blood flow is 
much higher, the bioavailability of cyclobarbital administered orally 
will be considerably lower. 
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The data presented in Table 20.1 suggest that equilibrium between 
blood/liver and blood/kidneys has been reached already after 2 min, 
since the ratios do not change further with time. For the blood/brain 
ratio the equilibrium is reached much slower. 
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CHAPTER 21 
PECULIAR PHARMACOKINETICS OF BRALLOBARBITAL AS A 
SOURCE OF COMPLICATIONS IN VESPARAXR INTOXICATION 
INTRODUCTION 
ρ 
Vesparax , a potent barbiturate-hydroxyzine combination (50 mg brallo-
barbital, 150 mg secobarbital, 50 mg hydroxyzine-HCl), has been used 
frequently in suicide attempts (Verheist, 1970). It is difficult to 
treat such intoxications successfully. In the course of a comparative 
study of barbiturates in rats, we studied also brallobarbital. In pre­
liminary studies was found that the hypnosis after oral administration 
of brallobarbital was much longer than after intravenous injection. 
Since there are also clinical indications that the toxic effects 
of Vesparax may be caused by brallobarbital, we have studied the phar­
macokinetics of brallobarbital in detail both in the intact rat and in 
the isolated perfused rat liver preparation. 
RESULTS 
Intravenous administration 
Figure 21.1 shows the time courses of a low and a high intravenous dose 
of brallobarbital in the same rat. The half-lives are about 3 h and in­
dependent of the dose. Intravenous injection of doses ranging from 25 to 
40 mg/kg results in the loss of the righting reflex within 15 sec and 
produces a quiet sleep; the blood concentration at the moment of awaken­
ing is about 40 mg/1 (Table 21.1). After high doses, however, the animals 
often die after 3-4 h, apparently by respiratory failure accompanied by 
convulsions. 
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200 240 
time (mm) 
Fig. 21.1 Time courses of brallobarbital follom-ng intravenous admini­
stration in the same rat · · 92 mg/kg 
О О 28 mg/kg 
Oral administration 
After oral administration there is a latent period of about 15-25 min. 
The onset of hypnosis coincides with convulsions and the sleep is much 
longer than after intravenous injection (Table 21.2). This corresponds 
with the sustained blood level, which becomes nearly constant after the 
absorption phase and starts to decrease only after 3-4 h. 
As brallobarbital is present as its calcium salt in the commercial 
R 
Vesparax tablet, this too was studied. Figure 21.2 presents the blood 
concentration-time curves of brallobarbital-Ca and the free acid (sus­
pended in 10% Tween 80) in the same rat. The calcium salt and the free 
acid gave blood curves similar to the sodium salt administered orally 
(see also Table 21.2). Doses administered orally are absorbed via the 
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TABLE 21.1 
Blood half-lives, sleeping times and blood concentrations at awakening 
in rats following intravenous administration of brallobarbital 
Dose 
(mg/kg) 
ti 
(min) 
180 
184 
183 
190 
195 
191 
176 
184 
Sleeping 
time 
(min) 
-
6 
15 
47 
58 
62 
+ 
_* 
Blood 
at 
concentration 
awakening 
(mg/l) 
-
35 
33 
45 
44 
44 
-
-
16 
29 
33 
39 
39 
42 
80 
92 
Mean 185+6 40+5 
+}£ died without auakening after 190 and 24b min respectively 
ao 
60 
e 40-
20-
10 40 80 120 160 200 240 280 320 360 400 
time (mm) 
Fig. 21.2 Time course of brallobarbital after oral administration in rats 
О calciim salt (9S mg/kg) 
Φ free acid (95 mg/kg) 
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TABLE 21.2 
Blood levels in rat following administration of 
brallobarbital orally and via the portal vein 
Dose 
(mg/kg) 
Blood concentration 
at time (min) 
30 60 
Oral administration 
20 
61 
75 
125 
95 
95 
14 
20 
39 
82 
54 
40 
14 
21 
38 
81 
52 
47 
120 
14 
24 
34 
81 
49 
53 
180 
13 
26 
34 
65 
47 
50 
(mg/1) 
240 
12 
25 
34 
60 
49 
49 
Latent 
period 
(min) 
-
-
25 
16 
16 
14 
Sleeping 
time 
(min) 
-
-
202 
334 
294 
315 
С ' 
aw 
(mg/1) 
-
-
34 
43 
49 
38 
Portal vein administration 
57 
60 
45 
66 
69 
53 
62 
68 
54 
57 
63 
45 
59 
62 
43 
45 
59 
40 
1) blood concentration at awakening 
mesentery blood system, which via the portal vein leads directly to the 
liver. Drugs, injected into the dorsal penis vein, however, first enter 
the general circulation (Nightingale, 1973). It was, therefore, interest­
ing to follow the fate of brallobarbital administered directly to the 
liver with exclusion of absorption processes. This was done in two ways: 
first by injection of the bprbiturate into the portal vein, secondly in 
the isolated perfused rat liver system. 
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Administration by the portal vein 
Injection of brallobarbital into the portal vein resulted in blood con­
centration-time curves, which have the same time course as found after 
oral administration. An example is shown in Figure 21.3. Therefore, ab­
sorption can be ruled out as the origin of the retarded elimination. 
blood cone ( m g / l , log scale) 
100 
8 0 
6 0 
40 
2 0 
v 
exp 15-1-73 
20mg Brallobarbital (57my/lcy ) 
portal vtfm 
W 120 200 
4 
'Ν ¡A , 
!E I I' 
QUO time (min) 
Fig. 21.3 Blood oonoentration-time eurve and tissue concentrations 
(тд/д) of brallobarbital following administration via the 
portal vein 
Liver perfusion 
The rate of elimination of brallobarbital in the isolated perfused rat 
liver system is slower than in the intravenous experiments. There is a 
highly significant difference between the heptabarbital half-life ratio 
and heptabarbital clearance ratio measured in the intact rat and in the 
perfusion (see also chapter 12, Tables 12.2, 12.3). 
Liver concentration 
In order to investigate if there is a difference in the amount of brallo­
barbital following the different routes of administration, liver concen­
trations were measured. The results presented in Table 21.3 show no es­
sential differences in the blood/liver concentration ratio following the 
different routes of administration. In spite of the high concentration of 
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TABLE 21.3 
Blood and liver concentrations of brallobarbital 
after different routes of administration 
Dose 
(mg/kg) 
Route of 
administration 
i.V. 
i.V. 
i.V. 
i.V. 
p.v. 
p.v. 
p.o. 
p.o. 
p.o. 
p.o. 
Time 
after 
dosage 
(min) 
2 
100 
120 
240 
240 
240 
400 
330 
24 
60 
Concentration 
blood 
(mg/1) 
52 
37 
34 
52 
50 
41 
53 
55 
114 
174 
in 
liver 
(mg/kg) 
89 
81 
68 
92 
80 
64 
112 
87 
152 
223 
Ratio 
blood 
liver 
0.58 
0.46 
0.50 
0.57 
0.63 
0.64 
0.47 
0.63 
0.75 
0.78 
32 
41 
41 
92 
57 
45 
115 
122 
150 
165 
•C.v., intravenous; p.v., portal vein; p.o.y oral administration 
brallobarbital, attained after intravenous injection, elimination is 
normal and this suggests that it is not brallobarbital itself which is 
responsible for the retarded elimination, observed after oral administra-
tion. 
Combination with other oompounds 
The retarded elimination may be caused by inhibition of the liver en-
zymes. Therefore, the influence of brallobarbital given orally on the 
R R 
elimination of heptabarbital, Eunarcon and Rectidon was studied. In 
the intact animal and in the perfusions the retarded elimination appeared 
to be restricted to brallobarbital, whereas the other barbitur.iu- was 
eliminated normally. Figure 21.4 presents a typical example whli KrcLidon . 
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blood cone (m^/l-.loyscale) 
« p . 19-1-73 
15mg· Eectidon ι ν 
Br О 
I II 
C=C-C C-NH 
C-C-C-C C-NH 
I II 
с о 
- ι 1 1 1— 
20 4 0 6 0 3 0 
exp 30-1-73 
30mg- Brallobarbital po 
ai time 5915mg Rectidon ι ν 
— ι 1 1 1 
20 40 60 80 100 
bme ( m m ) 
Fig. 21.4 Influence of brallobarbital administered orally on the elimi­
nation of an intravenous dose of Rectidon" 
a. Control RectidcmP (32 mg/kg) intravenously О О 
b. Brallobarbital (18 mg/kg) orally · · ., plus Rectidon 
(32 mg/kg) intravenously, 50 min later 
Further we have studied the influence of some hypothetical metabo­
lites of brallobarbital. According to Keding (1969) brallobarbital is 
metabolized in man according to the following scheme (Fig. 21.5). The 
principal urinary metabolites are compounds III and IV. Compound IV is 
used as ataractic drug under the name Ipronal , which is metabolized in 
man to non-barbiturate metabolites, such as compound X and XI (Bobranski, 
1961). Oral administration of these compounds resulted in a retarded 
elimination of brallobarbital, when administered intravenously 20 min 
afterwards. The blood concentration curves are the same as found in the 
oral experiments (Fig. 21.6). 
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Fig. 21.5 Hypothetieal scheme of the metabolism of brallobavbital after 
Keding (7969) 
I S-(2 '-bromoallyl)-S-allyl barbituric acid; II S-allyl-S-car-
boxymethyl barbituric acid; III S-acetonyI-S-allyI barbituric 
acid; IV 5-diaaetonyl barbituric acid; V S-acetonyl-S-(2'-
-bromoallyl) barbituric acid; VI 5-(2 '-bromoallyl)-5-carboxy-
methyl barbituric acid; VII S-allyl-5-(2'-hydroxypropyl) bar­
bituric acid; VIII 5-acetonyl-5-(2'-hydroxypropryl) barbituric 
acid; IX S-(2 '-bromoallyl)-5-(2 '-hydroxypropyl) barbituric 
acid; X a-allophanyl-a-allyl-y-valerolacton; XI a-allyl-y-
-valerolacton 
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200-
240 280 320 
time (mm) 
Fig. 21.6 Influenae of metabolites administered orally on the еігтіка-
tion of an intravenous dose of brallobarbital, given 20 min 
afteruards
 R 
О О Ipronal (SS mg/kg, orally); brallobarbital (40 mg/kg) 
m · Valerolaaton (63 mg/kg3 orally); brallobarbital 
(40 mg/kg) 
Δ Δ Reference, brallobarbital (104 mg/kg) orally 
Combination with secobarbital and hydroxyzine 
R 
We have investigated the influence of the other components of Vesparax 
on the elimination of brallobarbital. Table 21.4 shows that both compo­
nents increase the half-life of brallobarbital; secobarbital by a factor 
two and hydroxyzine is even more effective. 
Induction with phénobarbital 
Since our experiments suggested that the retardation of brallobarbital 
elimination after oral administration was due to one or more of its me-
tabolites, we decided to increase the formation of these metabolites by 
induction of the enzymic system with phénobarbital. Rats were pretreated 
with phénobarbital, 20 mg orally, for ten days. 
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TABLE 21.4 
Influence of other compounds on the blood half-life of brallobarbital 
Compound Dose 
(mg/kg) 
tj Sleeping Blood concentration 
brallobarbital time at awakening 
(min) (min) (mg/l) 
Secobarbital 
Hydroxyzine 
IpronalR 
Valerolacton 
53 
51 
60 
51 
55 
67 
53 
63 
380 
380 
500 
660 
400 
370 
520 
615 
204 
110 
120 
145 
131 
115 
220 
273 
37 
41 
41 
39 
37 
39 
40 
45 
The compound was administered orally; brallobarbital (35 mg/kg) was given 
intravenously 20 min afterwards 
Figure 21.7 shows the blood concentration-time curves of brallobar-
bital in the same rat, intravenously administered, before and after 
phénobarbital induction. The half-life is shortened with a factor 5 to 
35 min. Oral administration of brallobarbital in a phenobarbital-induced 
animal resulted in a blood concentration-time curve with a half-life of 
about 60 min (Fig. 21.8). An explanation may be that the breakdown of the 
metabolite(s) itself is also enhanced, the nett effect being a decrease 
in retardation. 
In addition to our rat experiments we studied the peculair behaviour 
of brallobarbital in dog. Figure 21.9 shows that also in this species the 
difference in rat of elimination between oral and intravenous dosage is 
present. This appears clearly from the difference in sleeping time. 
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blood cone ( mg/l:log scale) 
1 0 0 -
80-
60 
2 0 -
12 mg b r a l l o b a r b i t a l ι v. 
time ( mm) 
21.7 Blood canaentration-ttme owves of brallobarbital following 
intravenous admin-Lstraticn in the same r a t before (upper) and 
after (lower) phénobarbital induation 
Horizontal bars: sleeping times (min) 
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Fig. 21.9 Blood concentration-time curves of brallobarbital following 
intravenous and oral administration in a Beagle dog 
Horizontal bars: sleeping times (min) 
DISCUSSIOa 
Pottier (1951) has made similar findings to ourselves using mice. He 
found that sleeping times, following administration of brallobarbital 
and a series of structurally related barbiturates, were longer after 
oral than after intravenous dosage. However, this effect was not dis­
cussed. 
The convulsions, which are so characteristic of the "hypnosis" pro­
duced by brallobarbital orally, appear about 20-30 min after dosing, 
suggesting that they are caused by a metabolite rather than by brallo­
barbital itself. The differences in sleep patterns between the two routes 
of administration may be caused by differences in the formation of this 
metabolite. Unfortunately, in our G.C. analysis no metabolites of brallo­
barbital could be detected. For N-methylbrallobarbital the acetonyl-meta-
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bolite could be detected as well after oral as intravenous dosage. This 
N-methyl derivative too exhibits the difference in elimination between 
the two dosage forms as can be seen in Figure 21.10. 
blood cone (mg/l:log scale) • 
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Fig. 21.10 Time conrees of N-inethylbrallobarbital in the intact rat 
following intravenous (left), oral (middle) and portal vein 
(right) administration 
Unfortunately, the half-life of brallobarbital administered intra­
venously to phenobarbital-treated animals was not increased as we had 
anticipated. It may be that in induced animals the compound responsible 
for the retarded elimination is in turn broken down rapidly. This aspect 
requires investigation in detail. 
5-Allyl-5-(2,-hydroxypropyl) barbituric acid (Ipronal ) prolongs 
sleep induced by phénobarbital and hexobarbital (Hano, 1962) and some 
animals, receiving these barbiturates in sub-lethal doses, died. This 
supports our findings that the metabolism of brallobarbital is inhibited 
by Ipronal . 
R 
Another important finding concerning the toxicity of Vesparax is 
that the elimination of brallobarbital is also retarded by secobarbital 
and hydroxyzine. This is in agreement with the results of Hermans (1973) 
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and Gainotti (1967). According to the last author hydroxyzine provokes a 
longer duration of sleep in man and seems to be responsible for a slight 
somnolence upon awakening. 
Although further study will be necessary to elucidate the problems 
of the toxicity of Vesparax , it seems most likely that they are caused 
by a delayed elimination of brallobarbital, when taken orally. This in-
hibition seems to be due to a metabolite of brallobarbital formed es-
pecially after oral administration of this barbiturate and to an inhibi-
tion by the other components of Vesparax , namely hydroxyzine and seco-
barbital. 
On the basis of our findings we may conclude that, from a pharmaco-
kinetic point of view the specific combination of drugs as present in 
R 
Vesparax is far from optimal. 
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SECTION VI 
SPECIES AND SEX DIFFERENCES IN ELIMINATION OF BARBITURATES 
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CHAPTER 22 
COMPAÄISON OF THE PHABMACOKINETIC DATA OF BARBITURATES IN MAN AND RAT 
Studies on the pharmacokinetics and metabolism of drugs in experimental 
animals are of interest with regard to the evaluation of both the phar-
macodynamic properties and the toxicity of the compounds. However, in 
the extrapolation of these data to man species differences in response 
and metabolism must be considered. Despite the long tradition of barbi-
turates as hypnotics, there were until recently no reliable data on their 
pharmacokinetic behaviour in man. 
In the present chapter we have investigated if there is some con-
formity between our data found in rats and the pharmacokinetic parameters 
known in man. For the 5-ethyl-5-alkyl substituted derivatives in both 
species penultimate hydroxylation and oxidation is the main route of me-
tabolism (Freudenthal, 1973), while cyclobarbital, hexobarbital and 
heptabarbital are metabolized at the 3-position of the cycloalkenyl sub-
stituent (Gilbert, 1974; Mark, 1963). 
In Table 22.1 some pharmacokinetic data of barbiturates in man and 
rats are presented. The apparent volumes of distribution in both species 
do not show such big differences as the half-lives. Therefore, we may 
conclude that the differences in half-lives are based on differences in 
the metabolic activity in the two species. This appears directly from 
the clearance values. Investigations reported in the literature indicate 
that the hexobarbital oxidase activity of human adult liver enzymes lies 
below that of rat livers, the difference being, however, only a factor 
two (Pelkonen, 1973). The cytochrome Ρ 450 contents of human and rat 
liver are 13.6 and 31.0 nMol/g liver respectively. An explanation of the 
large difference between man and rat cannot yet be given in term of en­
zyme constants such as V , К and К , since a systematic study in liver 
m' m s' '
 J 
microsomes (or hepatocytes) has not been done in human material. 
As in the rat experiments we have correlated the clearance of the 
barbiturates to that of heptabarbital (Breimer, 1974). However, it should 
be noticed, that the data in man show a considerable intersubject varia­
tion and that in contrast with the rat experiments the heptabarbital 
166 
TABLE 22.1 
Comparison of some pharmacokinetic parameters in man and rat 
Compound Half-life App. volume Clearance Heptabarbital Ref 
distribution 
(h) (1/kg) (ml/min.kg) к ratio 
rat man ratio — rat man rat man ratio — rat man 
Heptabarb i ta l 
B u t o b a r b i t a l 
P e n t o b a r b i t a l 
Amobarbital 
V i n y l b i t a l 
C y c l o b a r b i t a l 
Hexobarb i ta l 
0 . 2 2 
3.50 
0 . 8 8 
0 . 6 5 
1.65 
0 . 8 3 
0 . 4 3 
7.7 
37.5 
2 2 . 3 
2 2 . 7 
2 4 . 0 
11.6 
4 .41 
35 
11 
25 
35 
14 
14 
10 
0 . 6 5 
1.35 
1.14 
0 . 9 6 
0 . 9 8 
1.45 
1.06 
1.31 
0 . 7 8 
0 .99 
0 .87 
0 .74 
0 .50 
1.10 
4 3 . 6 
4 . 1 
15.0 
16.5 
7.0 
17.4 
5 8 . 1 
1.92 
0 . 2 4 
0 .51 
0 .51 
0 . 3 6 
0 . 4 9 
3 .57 
23 
17 
29 
29 
19 
35 
16 
1.00 
0 . 1 3 
0 . 2 8 
0.41 
0.16 
0 . 3 6 
1.33 
1.00 
0 . 1 2 a 
0 . 2 7 a 
0 . 4 1 a 
0 . 1 8 a 
0 . 2 6 b 
1 . 9 2 b 
1 
1 
2 
3 
1 
1 
1 
1) Breimer (1974) 2) Ehmebo (1974) 3) BalasubramLan (1970) 
a. not sign-ificantty different Ρ > 0.20 
b. not aignifioantly different Ρ > 0.05 
clearance was not measured in the same subject. 
The data presented in Table 22.1 show that for the majority of the 
barbiturates the heptabarbital clearance ratios found in man and rat are 
similar. There was a strong correlation between the two species (r 0.991, 
s 0.054). This suggests that it is possible to predict the clearance 
values in man by studying relative values in rats. 
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CHAPTER 23 
SEX DIFFERENCES IN THE ELIMINATION OF HEXO-
BARBITAL AND HEPTABARBITAL IN THE RAT 
INTRODUCTION 
Several reports have been published on sex differences in drug meta­
bolism by rat liver. The magnitude of the sex difference varies with 
the substrate. Brodie (1968) reported a clear sex difference for hexo-
barbital, whereas for the hydroxylation of aniline no sex difference 
was found (Kato, 1965). The results of some preliminary experiments 
with the isolated perfused female rat liver are presented in this 
chapter. 
RESULTS 
Figure 23.1 shows the curves of heptabarbital and hexobarbital in the 
isolated perfused female rat liver. 
perfusate cone (mg/l.log scale) 
ΘΟ-
6 0 -
40-
2 0 -
1 0 -
• · heptabarbital (8rng) 
ж—х hexo barbital (6mg) 
^Wr· 
— ι 1—ι 1 1 1 1 1 1 1 1 1 1 1 r 
20 40 6 0 80 100 120 140 160 
time (mm) 
Fig. 23.1 Coneentraticn-time curves of heptabarbital and hexobarbital in 
the isolated perfused female rat liver 
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The half-lives and clearances of heptabarbital and hexobarbital are 238 
and 56 min and 0.64 and 2.80 ml/min respectively. The heptabarbital 
half-life and clearance ratio of hexobarbital are 0.24 and 4.38 respec­
tively. The half-life of hexobarbital is 4 times smaller and the clear­
ance 4.4 times larger than of heptabarbital. In the male rat as used 
throughout the previous chapters the rate of elimination of both barbi­
turates is 10-30 times faster. See chapter 13. 
DISCUSSION 
The clearance of heptabarbital in the isolated perfused female rat liver 
is a factor 34 lower as compared with the male rat liver perfusion; for 
hexobarbital this factor is approximately 11. According to Kato (1965) 
hexobarbital is metabolized about thrice as rapidly by the 9000 g liver 
supernatant of male rats as by that of female animals. The cytochrome 
contents of livers of male and female rats are of the same order of 
magnitude (Gram, 1970). The high sex differences found in the perfusions 
therefore cannot be attributed to different cytochrome Ρ 450 contents. 
Although many studies have been undertaken on sex differences in 
metabolizing activity, e.g. effect of starvation and steroids (Kato, 
1965), the nature of it is still obscure. 
Pharmacokinetic studies on barbiturates in man are mainly restrict­
ed to men. There is only one report on the pharmacokinetics of amobarbi-
tal in men and women (Balasubramaniam, 1970). According to this author 
there was no sex-dependent difference in aroobarbital metabolism. Since, 
however, the sex difference in the metabolism of barbiturates apparently 
varies markedly with the barbiturate studied, it would be recommendable 
to investigate the rate of elimination of a barbiturate such as hepta­
barbital in females. 
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SUMMARY 
This thesis describes pharmacokinetic studies concerning the hypnotic 
activity, kinetic behaviour and metabolism of a large number of barbitu­
ric acid derivatives in relation to their chemical structure. The studies 
have been carried out in vivo as well as in vitro; the in vivo studies 
were done with rats, while the in vitro experiments were performed in 
various rat liver preparations of gradual increasing simplicity, namely: 
the isolated perfused rat liver, the isolated rat hepatocyte suspension 
and the 9000 g rat liver supernatant fraction. Further the interaction 
of the barbiturates with the metabolizing епгуте system was studied by 
measuring К and К values. 
m s 
The relevance of the pharmacokinetic data obtained in rats have been dis­
cussed with respect to human sleep therapy. 
The above mentioned approaches are elucidated in the general introduction. 
In Section I, chapters 1 and 2, the theoretical aspects of pharmaco­
kinetics are discussed, such as the pharmacokinetic models used and the 
pharmacokinetic analysis of the data and the calculation of enzymic con­
stants from saturating curves. 
Section II contains the chapters concerning materials and methods. 
One of the main drawbacks in structure-activity relationship (SAR) 
studies on barbiturates is the use of small miscellaneous sets of barbi­
turates. In our study we have used large homologous series of barbitu­
rates, the synthesis of which is described in chapter 3. 
In chapter 4 the methods used in the intact animal experiments, are 
presented. The pharmacokinetic parameters were derived from blood concen­
tration-time curves, which were obtained from one animal. This was pos­
sible by using a special sampling technique, "the orbita punction". More­
over, in each series of experiments a reference compound was included to 
correct for interindividual variation in the drug metabolizing activity 
of the animals. 
Chapter 5 deals with the isolated perfused rat liver. In the majority 
of the pharmacokinetic studies using this preparation, a little attention 
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is paid to the physiological state and the drug metabolic performance of 
the liver. We have measured the liver blood flow and the bile production 
and determined the pH, pCO. and pO» before and after the liver at regu­
lar time intervals. In addition, in each perfusion heptabarbital was used 
as reference compound for the drug metabolizing activity of the liver. 
The clearance of a derivative studied was related to the clearance of 
heptabarbital (heptabarbital clearance ratio). 
In the chapters 6 and 7 the methods and evaluation of the experi­
ments with isolated rat hepatocytes and the 9000 g rat liver supernatant 
are described. It has been shown that the oxygen supply is the most 
critical factor in this sort of experiments. 
The last three chapters of this section describe the methods for 
the determination of partition coefficients, К values and the analysis 
of the samples. In chapter 10 some tables are presented, showing the re­
lative G.C. retention times of the barbiturates used in this study to­
gether with those of the metabolites which could be detected in our 
assay. 
Section III contains the experimental chapters. In the chapters 11, 
12 and 13 a comparison is made between the elimination of the barbitu­
rates in vivo and in the isolated perfused rat liver system. The rate of 
elimination of the barbiturates is clearly dependent on the length of the 
side chain at the 5-position of the barbituric acid nucleus; the bromo-
allyl substituted barbiturates are cleared more rapidly than their allyl 
homologues and N-methylation of the barbiturates results too in a higher 
clearance. A relationship was found between the rate of disappearance of 
the barbiturate and their lipophilicity, which was expressed either as 
octanol/water or hepatocyte/water partition coefficient. For the majo­
rity of the compounds a good correlation was found between the clearance 
in vivo and in the perfusions. An exception was formed by some bromoallyl 
substituted barbiturates, which displayed in the perfusion a considerably 
lower heptabarbital clearance ratio than in the intact animal. 
Chapter 14 presents the pharmacokinetics of a number of barbiturates 
in the isolated rat hepatocyte suspension. It was shown that for the ma­
jority of the compounds studied, the heptabarbital clearance ratio was 
similar to that found in the perfusion studies. However, the absolute 
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clearances, corrected for the number of cells, suggest that the isolated 
rat hepatocyte suspension has a higher metabolic activity than the iso­
lated perfused liver. 
Chapter 15 deals with the pharmacokinetics of barbiturates in the 
9000 g rat liver supernatant. The pharmacokinetic behaviour of the ma­
jority of the barbiturates studied was different from that found in the 
hepatocyte suspension. Some compounds are metabolized much faster than 
in the hepatocyte suspension, as appears from the heptabarbital clear­
ance ratio. This phenomenon is discussed and associated with differences 
in transport processes between these metabolic test systems. 
In chapter 16 the binding of the barbiturates to cytochrome Ρ 450 
has been studied. The bromoallyl substituted barbiturates have a higher 
affinity for cytochrome Ρ 450 than their allyl homologues; N-methylated 
barbiturates too display a higher affinity for cytochrome Ρ 450 than 
their non-methylated homologues. In all homologous series the affinity 
for cytochrome Ρ 450 seems to increase with longer side chains. However, 
in the 5-ethyl-5-alkyl series the derivatives with an octyl and nonyl 
substituent clearly have a lower affinity for cytochrome Ρ 450 than the 
hexyl and heptyl substituted barbiturates. Apparently the length of the 
side chain is a factor to reckon with. 
Further some preliminary results of the determination of Michaelis-
-Menten constants (K ) from curves obtained following administration of 
m 
a saturating dose to liver perfusions are presented. The К values ob­
lìi 
tained from these curves differ from the values obtained with the con-
ventional methods (i.e. Lineweaver-Burke plots). Phénobarbital induction 
apparently does not affect the К value; the metabolic capacity of the 
liver, however, is increased considerably. 
In chapter 17 the pharmacokinetics of some barbiturate metabolites 
have been studied. The alkyl and cycloalkenyl substituted barbiturates 
are converted to hydroxy-metabolites which in turn may be metabolized 
further to their keto-homologues. 
In chapter 18 the metabolic differences between intact cell and 
subcellular test systems are discussed. In the intact cell systems, such 
as the intact rat, liver perfusion and isolated hepatocyte suspension, 
the alcoholic barbiturate metabolites are converted further to the keto-
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nes, whereas in the 9000 g rat liver supernatant the hydroxy-metabolites 
are not converted further. Ethanol inhibits the metabolism of the hy-
droxy-metabolites, whereas the metabolism of the parent compounds re-
mains unaffected. This suggests that the metabolism of the parent barbi-
turates and their hydroxy-metabolites is mediated by different enzymes. 
Section IV deals with the identification of the various barbiturate 
metabolites. Methylation and silylation techniques have been used to im-
prove the G.C. response and the separation of the hydroxy- and keto-me-
tabolites. 
Section V deals with the pharmacokinetics of barbiturates following 
different routes of administration. Chapter 20 shows that the half-lives 
of butobarbital and cyclobarbital are independent from the route of ad-
ministration. The bioavailability of cyclobarbital is much lower than 
that of butobarbital. 
Chapter 21 deals with the pharmacokinetics of brallobarbital follow-
ing intravenous, oral and portal vein administration. It was shown that 
after oral and portal vein administration the half-lives of brallobarbi-
tal and its N-methyl homologue were longer than after intravenous ad-
ministration. Moreover, it was found that the half-life of brallobarbital 
was increased following administration of secobarbital and hydroxyzine. 
From these results it has been concluded that the combination of drugs as 
R 
present in Vesparax (50 mg brallobarbital-Ca, 150 mg secobarbital-Na and 
50 mg hydroxyzine-HCl) is far from optimal. 
In Section VI species and sex differences in the elimination of bar-
biturates have been studied. In chapter 21 a comparison is made between 
the pharmacokinetic data obtained in rat and man. It is shown that rats 
metabolize the barbiturates more rapidly than man; the values, however, 
of the clearances relative to heptabarbital were similar in both species. 
This suggests that it is possible to predict the clearance values in man 
by studying relative values in rats. 
In the last chapter of this study some preliminary results of sex 
differences in clearance of heptabarbital and hexobarbital are presented. 
Heptabarbital is eliminated a factor 30 as low in the female rat liver 
perfusion as compared with the male rat liver perfusion. For hexobarbital 
this factor is about 11. 
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Our studies indicate clearly that the results obtained with each in 
vitro technique cannot be extrapolated directly to the in vivo situation 
without considering the limitations of each technique. The differences 
in morphological features of the liver cells, the organization of the 
liver and the circulatory aspects have to be taken into consideration. 
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SAMENVATTING 
In dit proefschrift is farmacokinetisch onderzoek beschreven betreffende 
de hypnotische werking, farmacokinetiek en metabolisme van een groot 
aantal barbituraten in relatie tot hun chemische structuur. Het onder-
zoek is uitgevoerd zowel in vivo als in vitro. De in vivo experimenten 
werden gedaan met ratten; de in vitro proeven werden uitgevoerd in ver-
schillende rattelever preparaten met een geleidelijk afnemende complexi-
teit, namelijk: de geïsoleerde doorstroomde rattelever, een suspensie 
van geïsoleerde rattelever parenchym cellen en de 9000 g supernatant 
fractie van de rattelever. Verder werd de interactie barbituraat-enzym 
onderzocht door het meten van de К en К waarden. 
m s 
De betekenis van de farmacokinetische resultaten, gevonden in ratten, 
voor de slaaptherapie in de mens wordt ter discussie gesteld. 
De hierbovengenoemde benaderingen worden toegelicht in de algemene in­
leiding. 
In Sectie I, hoofdstukken 1 en 2, worden de theoretische aspecten 
van de farmacokinetiek behandeld, zoals het gebruik van de verschillende 
modellen, de farmacokinetische verwerking van de meetpunten en het be­
palen van enzym constanten met behulp van verzadigingscurven. 
Sectie II bevat de hoofdstukken die handelen over de gebruikte 
stoffen en methoden. Een van de meest beperkende factoren in reeds ge­
publiceerd werk over de relatie structuur-werking van barbituraten is 
het gebruik van een klein aantal, qua structuur totaal verschillende bar­
bituraten. In ons onderzoek hebben we gebruik gemaakt van grote reeksen 
homologen. De synthese hiervan wordt behandeld in hoofdstuk 3. 
Hoofdstuk A geeft de methoden, die gebruikt werden voor de proeven 
met intacte ratten. De farmacokinetische parameters werden bepaald uit 
curven, die verkregen werden van één dier. Dit was mogelijk door een 
speciale bloedafname techniek te gebruiken, "de orbita punctie". Boven-
dien werd in elke serie experimenten een referentie stof meegenomen ter 
correctie voor variatie in metabole activiteit tussen de verschillende 
dieren. 
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In hoofdstuk 5 wordt de leverperfusie behandeld. In de meeste 
artikelen over farraacokinetisch onderzoek, verricht met deze techniek, 
wordt weinig aandacht besteed aan de fysiologische toestand en activi­
teit van de lever. Wij hebben de bloedstroom door de lever en de gal-
produktie gemeten en verder op gezette tijden de pH, pCO. en p0„ ббг 
en achter de lever bepaald. Tevens werd in elke perfusie heptabarbital 
meegenomen als referentie voor de metabole activiteit van de lever. De 
klaring van de onderzochte barbituraten werd gerelateerd aan de klaring 
van heptabarbital. 
Hoofdstukken 6 en 7 beschrijven de methoden, gebruikt voor de ex­
perimenten met geïsoleerde levercellen en de 9000 g rattelever super-
natant. In beide preparaten blijkt de zuurstof toevoer de kritische 
factor te zijn. 
De laatste drie hoofdstukken geven de bepalingsmethoden voor de 
verdelingscoëfficiënten, К waarden en de analyse van de monsters. In 
hoofdstuk 10 worden de relatieve retentietijden voor de onderzochte bar­
bituraten opgegeven, samen met die van de metabolieten die gaschromato-
grafisch aangetoond konden worden. 
Sectie III bevat de experimentele hoofdstukken. In de hoofdstukken 
11, 12 en 13 wordt een vergelijking gemaakt tussen de klaring van de 
verschillende barbituraten in de intacte rat en in de perfusies. De 
snelheid, waarmee de barbituraten uit het bloed verwijderd worden, is 
duidelijk afhankelijk van de substituent op de 5-plaats van de barbi­
turaat ring; de broomallyl gesubstitueerde barbituraten worden sneller 
gemetabolizeerd dan hun allyl homologen, terwijl de N-methyl derivaten 
ook sneller geklaard worden dan de niet gemethyleerde barbituraten. Voor 
de meeste barbituraten bestaat er een goede overeenkomst tussen de eli­
minatie in de rat en in de perfusie. Een uitzondering wordt hier gevormd 
door enkele broomallyl gesubstitueerde barbituraten, die in de perfusie 
een duidelijk lagere klaring, gerelateerd aan heptabarbital, hebben dan 
in de intacte rat. 
Hoofdstuk 14 behandelt de farmacokinetiek van een aantal barbitu­
raten in de levercel suspensie. Voor de meeste barbituraten blijkt de 
klaringsratio t.o.v. heptabarbital overeen te stemmen met die welke in 
de perfusie gevonden werd. De absolute waarden, gecorrigeerd voor het 
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aantal cellen, doen echter vermoeden dat de cel suspensie een hogere 
metabole activiteit bezit dan de geïsoleerde lever. 
Hoofdstuk 15 gaat over de farmacokinetiek in de 9000 g rattelever 
supernatant. Voor de meeste barbituraten was er een verschil, vergeleken 
met de cel suspensie. Sommige barbituraten werden veel sneller omgezet. 
Dit fenomeen wordt besproken en in verband gebracht met verschillen die 
er bestaan tussen beide modellen in transport door celwanden. 
In hoofdstuk 16 wordt de interactie van de barbituraten met cyto-
chroom Ρ 450 besproken. De broomallyl en de N-methyl barbituraten bezit­
ten een hogere affiniteit voor cytochroom Ρ 450 dan respectievelijk de 
allyl en niet gemethyleerde verbindingen. In alle series blijkt de af­
finiteit voor cytochroom Ρ 450 groter te worden naarmate de zijketens 
langer worden. In de 5-ethyl-5-alkyl serie blijken de octyl en de nonyl 
derivaten echter een lagere affiniteit te bezitten dan de hexyl en de 
heptyl verbindingen. Blijkbaar begint voor de octyl en de nonyl derivaten 
de lengte van de zijketen een storende factor te worden. 
Verder worden enige voorlopige resultaten getoond betreffende de 
bepaling van Michaelis-Menten constanten (K ) uit curves, verkregen na 
m 
toediening van een verzadigende dosering aan leverperfusie. Deze К 
waarden verschillen van die, welke op de conventionele manier (Line-
weaver-Burke) verkregen worden. Inductie met phénobarbital geeft geen 
verandering van de К , wel een duidelijke verhoging van de metabole ea­
rn 
paciteit van de lever. 
In hoofdstuk 17 wordt de farmacokinetiek van enkele barbituraat 
metabolieten onderzocht. De alkyl en cycloalkenyl gesubstitueerde barbi­
turaten worden omgezet in hydroxy-verbindingen, die op hun beurt verder 
gemetabolizeerd kunnen worden tot ketonen. 
In hoofdstuk 18 worden de verschillen in metabolisme tussen de test 
systemen met intacte cellen en subcellulaire fracties besproken. In de 
systemen met intacte levercellen, zoals de intacte rat, leverperfusie 
en de levercel suspensie, worden de hydroxy-metabolieten omgezet in 
ketonen, terwijl dit in de 9000 g rattelever supernatant niet gebeurd. 
Verder blijkt ethanol het metabolisme van de hydroxy-metabolieten te 
remmen, terwijl het metabolisme van de barbituraten zelf onaangetast 
blijft. Dit suggereert dat de omzetting van barbituraten en hydroxy-
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barbituraten verloopt via verschillende enzymsystemen. 
Sectie IV behandelt de identificatie van de verschillende barbitu-
raat metabolieten. Er is gebruik gemaakt van verschillende technieken, 
zoals methylering en silylering, om de gaschromatografische response en 
de scheiding van de metabolieten te verbeteren. 
Sectie V behandelt de farmacokinetiek van barbituraten bij verschil-
lende toedieningsvormen. In het eerste hoofdstuk van deze sectie wordt 
aangetoond dat de half waardetijd van zowel butobarbital als cyclobarbital 
onafhankelijk is van de wijze van toediening. De biologische beschikbaar-
heid van cyclobarbital is echter veel lager dan die van butobarbital. 
Hoofdstuk 21 behandelt de farmacokinetiek van brallobarbital na 
intraveneuze en orale toediening en toediening via de poortader. Er werd 
gevonden dat na orale en poortader toediening de halfwaardetijden van 
brallobarbital en zijn N-methyl homoloog veel langer zijn dan na intra-
veneuze toediening. Bovendien werd aangetoond dat de halfwaardetijd van 
brallobarbital verlengd was na toediening van secobarbital en hydroxyzine. 
Hieruit wordt geconcludeerd dat de combinatie van stoffen, zoals bij 
R 
Vesparax (50 mg brallobarbital-Ca, 150 mg secobarbital-Na en 50 mg hy-
droxyzine) verre van optimaal is. 
In Sectie VI worden species en sex verschillen in de eliminatie 
van barbituraten besproken. In hoofdstuk 21 wordt een vergelijking ge-
maakt tussen de resultaten verkregen in de rat en in de mens. Ratten 
blijken barbituraten veel sneller om te zetten dan mensen; de klaringen, 
gerelateerd aan heptabarbital, blijken in beide species gelijk te zijn. 
Dit suggereert dat het mogelijk is klaringsconstanten in de mens te voor-
spellen door de relatieve klaringen in de rat te bestuderen. 
In het laatste hoofdstuk van dit proefschrift worden enkele voor-
lopige resultaten van sex verschillen in de eliminatie van heptabarbital 
en hexobarbital besproken. Heptabarbital blijkt dertig maal zo langzaam 
gemetabolizeerd te worden door levers van vrouwelijke ratten dan van 
mannelijke ratten, voor hexobarbital is deze factor circa 11. 
Uit ons onderzoek blijkt duidelijk dat de resultaten verkregen met 
de diverse in vitro technieken niet direct geëxtrapoleerd mogen worden 
naar de in vivo situatie, zonder zich de beperkingen van iedere techniek 
te realiseren. Men moet rekening houden met de verschillen in de morfo-
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logie van de levercellen, de structuur van de lever en de aspecten be-
treffende de circulatie. 
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